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Abstract 
Nine monothiosemicarbazone ligands were prepared by Schiff-base condensation 
reactions of thiosemicarbazide and the appropriate aryl aldehyde or ketone. These 
compounds were isolated as air- and moisture- stable solids and were characterized 
using NMR and IR spectroscopies, as well as mass spectrometry and elemental 
analysis in the case of ligand 3-terl.-butyl-2-hydroxy-benzaldehyde 
thiosemicarbazone, which is a new compound. 
Four of these ligands were reacted with precursors of type Pd(L)2CI2 yielding eight 
tridentate thiosemicarbazone Pd(II) complexes with general formula [Pd( 3-0,N,S-
thiosemicarbazone)(L)] (L = PPh3 or 4-picoline). Six of these complexes are new 
compounds and were fully characterized using NMR and IR spectroscopies, mass 
spectrometry and elemental analysis. In addition, the solid state structures of three 
complexes were elucidated using single crystal X-ray diffraction methods. 
Reaction of the thiosemicarbazone ligands with K2[PdCI4] yielded either tetranuclear 
tridentate [C,N,S] complexes, formed by cyclometallation of the orlha-carbon, imine 
nitrogen and thiolato sulfur with metal centers linked via Pd-Sbridging bonds to give a 
tetrameric structure or dimeric complexes, where the ligand coordinates to 
palladium as a singly negative bidentate [N,S] donor and each metal center is 
bridged by two chlorine atoms. The bridging bonds in these precursors were cleaved 
with the tertiary phosphine PPh3 to yield monomeric cyclometallated complexes. All 
of these complexes are new compounds and were fully characterized using standard 
spectroscopic, spectrometric and analytical techniques. The molecular structures of 
one tridentate and one bidentate thiosemicarbazone Pd(II) complex were solved 
using single crystal X-ray diffraction and confirm the structural nature of the 
mononuclear complexes synthesized. 
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Selected mononuclear complexes and their corresponding free ligands were 
screened for preliminary biological activity as anticancer and antimalarial agents. 
Two complexes exhibited good cytotoxic activity against most cancer cell lines 
screened, while a free ligand was found to be the most potent inhibitor out of all 
compounds tested. Against the P. fa/ciparum strains, none of the free ligands were 
active at the highest concentration tested while two complexes showed superior 
antiplasmodial activity against the chloroquine sensitive (010) strain. 
Catalytic studies using selected palladium(lI) complexes show that tridentate 
thiosemicarbazone Pd(lI) complexes successfully catalyze Suzuki-Miyaura carbon-
carbon coupling between phenyl boronic acid and twb aryl bromide substrates in the 
presence of water and in air. Moderate to good percentage conversions were 
obtained with the complexes exhibiting selectivity towards the 4-bromo-anisole 
substrate. 
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Chapter 1: General Survey of Tridentate Monothiosemicarbazone 
Palladium(ll) Complexes 
1.1. Brief Background on Thiosemicarbazones 
Thiosemicarbazones are Schiff-base type compounds that are noted for their 
pharmacological properties, particularly as antiparasitic,1-6 antibacterial 7-9 and 
antitumoral agents.10-14 These compounds contain a thiourea moiety which has 
several donor atoms (Figure 1.1.) and are capable of acting as multidentate ligands 
toward a metal. 
R1 = aryl, alkyl, heterocyclic group 
R2 = H, aryl, alkyl group 
Thiourea moiety 
R3 = H, alkyl, aryl, heterocyclic group 
~ = H, alkyl, aryl, heterocyclic group 
Figure 1.1: General structure of thiosemicarbazones 
In addition to the thiourea moiety, varying the R substituents gives rise to a wide 
range of compounds.15 For example, thiosemicarbazones derived from aldehydes 
have a hydrogen atom (R2) on the C2 carbon and the R1 substituent may be an alkyl, 
aryl or heterocyclic group. Ketone-derived thiosemicarbazones can have an aryl or 
alkyl group as the R2 substituent and in some cases the ketone used is cyclic leading 
to the C2 carbon being part of a ring. The substituents (R3 and R4) on the N1 nitrogen 
atom can be two hydrogens or hydrogen and an alkyl, aryl or heterocyclic group. 
While several synthetic routes for the preparation of thiosemicarbazones have been 
published,16-22 there are three general routes used to synthesize 
thiosemicarbazones. The first route involves the preparation of methyl 
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hydrazinecarbodithioate (Scheme 1.1.).16,22 This precursor is then condensed with 
different ketones or aldehydes to give a Schiff base type methyl hydrazine 
carbodithioate precursor (II). Amination of II yields the desired thiosemicarbazone 
(III). 
R' 
I~ ~ NHR" R~N/y 
III S 
R" = H, alkyl, aryl, heterocyclic group 
Scheme 1.1. 
R"-N~ 
~R' 
R = aryl, alkyl, heterocyclic group 
R' = H, aryl, alkyl group 
II 
The second route involves the condensation of a hydrazine derivative with an 
isothiocyanate to give the desired thiosemicarbazone and the third route, by far the 
most common method of preparation, yields the thiosemicarbazone by Schiff base 
condensation of an aldehyde or ketone with thiosemicarbazide.1,16 
1.2. Bonding Modes of Monothiosemicarbazones 
Monothiosemicarbazone ligands exist as an equilibrium mixture of the thione (I, 
Figure 1.2.) and thiol (IV) tautomers. Tautomer I can bind to a metal as a neutral 
ligand and tautomer IV can bond to a metal as an anionic ligand upon loss of the 
thiol proton (V).23 
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IV V 
Figure 1.2.: Structures of tautomers I, IV and anionic V 
Several bonding modes have been observed for both the neutral and anionic forms 
of monothiosemicarbazones. In the neutral form, these ligands can bind via the S 
atom only (VI,24,25 Figure 1.3.), with the sulfur bridging two metal centers (VII),24,26 
the imine nitrogen and thione sulfur chelating one metal center (VIII) 27,28 or with 
imine nitrogen and sulfur chelation to one metal center and sulfur bridging a second 
metal center (IX).28 In addition to these bonding modes, if the substituent at the imine 
carbon contains a donor atom, three other bonding modes are possible; tridentate 
coordination of donor atom, imine nitrogen and sulfur to metal center (X),29 tridentate 
coordination as in X and the sulfur bridging (XI) 30 or the donor atom bridging (XII) 31 
another metal center. 
VI 
XII 
M = metal center 
D = donor atom 
L" = ancillary ligands 
VIII 
Figure 1.3.: Various bonding modes of thiosemicarbazones in the neutral form <I> 
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For the anionic form V, the same bonding modes are observed (with sulfur in the 
anionic thiolate form) 30-38 as well as bis-chelation of the sulfur and the hydrazinic 
nitrogen to a metal center (XIII,39 Figure 1.4.) or the sulfur bridging two metal centers 
and the hydrazinic nitrogen coordinating to a third metal center (XIV).4o 
XIII 
Figure 1.4.: Additional bonding modes of anionic tautomer (V) 
1.3. Tridentate Aromatic and Heteroaromatic derived Monothiosemicarbazone 
Paliadium(lI) Complexes 
The study of the coordination chemistry of thiosemicarbazones has long been of 
interest with the earliest review being published in 1974.41 Since then there have 
been extensive reports on the synthesis of thiosemicarbazone complexes with 
metals including vanadium,42,43 zinc,44 cobalt,45 gold,46 nickel,47,48 silver,49 copper,50-
52 and iron.53 As mentio ed in Section 1.1., varying the substituents of the C2 carbon 
of thiosemicarbazone ligands influences their bonding mode to the metal. If the 
substituent contains a donor atom, it is possible for the thiosemicarbazone ligand to 
bond to palladium in a tridentate manner. Cyclopalladated complexes with tridentate 
thiosemicarbazones prepared via C-H activation of the C2 substituent have also 
been described. 54-56 
Due to the extensive number of literature reports available as well as the relevance 
of literature examples to this research project, this general survey of the literature 
focuses on the synthesis of tridentate aromatic- or heteroaromatic-derived 
monothiosemicarbazone paliadium(ll) complexes. 
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1.3.1 Palladium(lI) Complexes Containing Tridentate [N,N,S] Donor 
Monothiosemicarbazones 
Literature reports regarding palladium complexes with tridentate [N,N,S] donor 
thiosemicarbazone ligands mainly comprise thiosemicarbazones derived from 
pyridine-2-carboxaldehyde or its analogues. Kovala-Demerlzi and co-workers have 
synthesized a variety of these complexes.10.57-62 When the thiosemicarbazone ligand 
is reacted with lithium tetrachloropalladate in an approximate 1:1 molar ratio, a 
chloro palladium complex (1) is yielded.10.58.59.61.62 The ligand coordinates to 
palladium via the pyridine and imine nitrogen atoms and thiolato sulfur forming two 
five membered chelate rings and the fourth coordination site on palladium is 
occupied by a chloride ion. 
Paliadium(lI) complexes of type 2 where two thiosemicarbazone ligands bond to one 
metal center are isolated when the ligand:metal ratio is approximately 2:1. 10.58.60 One 
ligand bonds to palladium in the similar trident te fashion as 1 and a second 
thiosemicarbazone ligand is bonded to the metal as a monodentate donor via the 
thiolato sulfur. 
1 
b and 28: R1 .. H; ~ .. R3 • H 
1b and 2b: R1 "' Me; ~ .. H, R3• Et 
1c: R1 .. H; N1 .. '-Bmethytenelmlne ring 
1d and 2c: R1 • Me; N1 .. '-Bmethytenelmlne ring 
18: R1 .. Ph; R1 = Me, ~=Ph 
1f: R1 • H; N1 "' 1-(2-pyr1dy1)-piper1zanyl 
111: R1 .. Me; N1 • 1-(2-pyr1dy1)-p1perlzanyl 
1h: R1 .. Me; R1 = H, ~ = Et 
Figure 1.5. Structures of complexes of type 1 and 2 
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The formation of paliadium(lI) complexes of type 2, where the ligands form a 
tridentate/monodentate system instead of a bis-bidentate chelate system are 
governed by several factors. The preference of palladium to bind to sulfur over 
nitrogen and its requirement to be as close to square-planar geometry as possible 
may play a role as well as the need of the ligands to preserve their planar, 
conjugated structures as far as possible. In addition, the tricyclic ring system 
comprising the pyridine ring, N-Pd-N chelate ring and N-Pd-S chelate ring of the 
tridentate ligand would have higher stability compared to a bis-bidentate chelate 
system.10 
A mononuclear complex of type Pd(.,3-N,N,S-thiosemicarbazone)(PPh3) (3, Figure 
1.6.) was isolated when pyrrole-2-carbaldehyde thiosemicarbazone was reacted with 
the precursor, Pd(PPh3nCI2, in the presence of abase. 37 A ligand to metal ratio of 
1: 1 or 1:2 invariably gave complex 3 upon deprotonation of the pyrrole and 
hydrazinic nitrogens. When this method was extended to pyridine-2-carbaldehyde, a 
chloro palladium complex of type 1 was isolated. 
3 
Figure 1.6. Structure of complex 3 
The difference in ancillary ligand occupying the fourth coordination site on palladium, 
despite the same synthetic method being employed, was reasoned in terms of the 
presence of an acidic hydrogen. Deprotonation of the pyrrole nitrogen facilitates 
coordination of the thiosemicarbazone as a dianionic ligand thus retaining one 
triphenylphosphine. The absence of an acidic hydrogen on the pyridine nitrogen 
means that the ligand bonds to palladium as a singly negative tridentate ligand 
favouring retention of a chloride ion and loss of triphenylphosphine.37 
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The synthesis of a tetranuclear palladium(lI) complex with 6-amino-5-formyl-1,3-
dimethyl uracil thiosemicarbazone tridentate ligand (Scheme 1.2.) has also been 
published.63 Reaction of the ligand (4) with potassium tetrachloropalladate in 
equimolar amounts in DMF gave a mononuclear complex with sulfur coordinating in 
the thione form (48). However, recrystallisation of this complex from DMF-water 
solutions yielded the tetrameric complex (4b) containing a Pd4S4 core that is formed 
by palladium-sulfur bridging bonds and sulfur is now coordinated to the metal in the 
thiolato form. 
DMF-water 
Scheme 1.2. 
1.3.2 Palladium(lI) Complexes Containing Tridentate [O,N,S] Donor 
Monothiosemicarbazones 
Mononuclear palladium complexes, of type 5 (Figure 1.7.), containing tridentate 
[O,N,S] thiosemicarbazone ligands have been synthesized by reaction of 2-hydroxy 
aryl thiosemicarbazone derivatives with a [Pd(LhCI2] (where L = PPh3 or 4-picoline) 
precursor in the presence of a base.23,37,64,65 In all of the complexes, the ligand forms 
a six and five membered chelate ring with palladium upon loss of the phenolic and 
hydrazinic protons. Triphenylphosphine or 4-picoline occupies the fourth coordination 
site on palladium and the metal has an approximately square-planar geometry. 
Binuclear complexes (6) formed by bridging diphenylphosphinoalkanes have recently 
been reported.56 These complexes were prepared using a similar method as for 
complexes of type 5. 
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511: R. R1.~. R3 = H; L = PPha 
5b: R. R1. ~. W = H. L = 4-plcollne 
5c: R. ~. W = H. R1 = CH3; L = PPha 
ScI: R. ~. W = H. R1 = CH3; L = 4-plcollne 
511: R. R1. ~ = H. R3=CsH5; L= PPh3 
8 
51: R= C4H4. R1.~. R3= H; L= PPh3 
5g: R = C4~. R1. R2. W = H; L = 4-plcollne ~ = dlphenylphoshlnomethane (68); dlphenylphoshlnopropane (ab) 
511: R = C4H4. R1 = ~ = H. R3 = CsH5; L = PPh3 P P 
51: R = C4~. R1 = ~ = H. W = CH3; L = PPh3 R-~-! ' ~rNIJ'R' UO--IPd 5 
I I 
• • 4 
71: R = R1 = H or CH3. ~ = W = H 
7b: R=C4~' R1 =HorCH3. ~ = W= H 
Figure 1.7. Structure of mononuclear, binuclear and tetra nuclear paliadium(lI) complexes containing 
tridentate salicylaldehyde thiosemicarbazone derivatives 
Tetranuclear complexes (7) have been prepared by reaction of the salicylaldimine-
thiosemicarbazone with sodium tetrachloropalladate using triethylamine as proton 
abstractor.64 In complexes 5 - 7, the ligand acts as a dianionic tridentate donor 
toward palladium. If the ligand is reacted with a palladate salt without the use of a 
base then it coordinates to palladium as a uninegative tridentate donor to the metal 
(8) with sulfur bonding as a neutral donor (Scheme 1.3.).67 
oc" ~N./~yNHR_L....;;i2,-[P_dC_I.cl __ • Methanol # OH S 
Scheme 1.3. 
~r~yNHR 
o-r s 
CI 
Sa: R= H 
8b: R= CH3 
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Paliadium(lI) complexes of 2-hydroxy-acetophenone thiosemicarbazone analogues 
have been prepared by reaction of the ligand with a palladate salt. It was 
demonstrated that changes in pH and stoichiometric ratios affect the type of complex 
isolated (Figure 1.8.). When a metal:ligand ratio of 1:1 is used at approximately pH 4, 
mononuclear complexes of type 9 were obtained.68•69 When the pH of the reaction 
mixture was raised to approximately 9 using aqueous ammonia, the favoured 
product was the trinuclear complex of type 10.38,68,69 A metal:ligand ratio of 1:2 
reacted at pH 9 yielded complex 11, where one ligand is coordinated as a dianionic 
tridentate donor to palladium and the second thiosemicarbazone ligand is 
coordinated in a monodentate fashion via the thiolato sUlfur.70 
R2 
I 
/NiNHRl 
-"'::::::N ~ 
I 
N N ~ri'~ 
O-Pd--S 
I 
CI 
IIII:Rl=~H5 
9b: Rl = c"H7 
O-jd--j 
, 3 
10.: Rl = H. ~ = ~H5. R3 = H 
10b: Rl = H. R2 = c,,~. R3 = H 
10c: Rl = 4-OCHa• R2 • CH3. R3 = CH3 
11 12 
Figure 1.8. Structures of complexes 9 -12 
The reaction of phenanthrenequinone thiosemicarbazone with potassium 
tetrachloropalladate yields a mononuclear complex (12) where the 
thiosemicarbazone ligand coordinates to palladium as a uninegative [O,N,S] donor 
via the carbonyl oxygen, imine nitrogen and thiolato sulfur.71 
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1.3.3 Palladium(II) Complexes Containing Tridentate [C,N,S] Donor 
Monothiosemicarbazones 
The preparation of cyclopalladated aryl thiosemicarbazone complexes can be 
achieved by treatment of an aryl thiosemicarbazone with a tetrachloropalladate salt 
or palladium acetate (Scheme 1.4.).54,55,72,73 The product is a tetrameric complex (14) 
with the ligand bonding as a tridentate [C,N,S) donor to palladium forming two fused 
rings at the metal center and a Pd4S4 core that is formed by Pd-Sbrldging bonds. 
(I) (II) 
13: Rl, R2, R = alkyl or H 14 15 
(I): Pd(OAc h or tetrachloropallac:late salt; (II): tertiary phosphine 
Scheme 1.4. 
The palladium-sulfur bridging bond can be cleaved with a nucleophile such as a 
tertiary phosphine, yielding a mononuclear ortho-palladated complex (15). The 
palladium-sulfur chelating a-bond remains intact and this can be reasoned in terms 
of Pearson's concept. 74 Palladium is a borderline/soft acid and will prefer to bond to 
borderline or soft bases. Sulfur is a soft base and thus, the palladium-sulfur chelating 
bond in thiosemicarbazone complexes is much stronger than in its corresponding 
[C,N,c) and [C,N,N) complexes where the metal-oxygen and metal-nitrogen bonds 
are easily cleaved with a tertiary phosphine leading to opening of the chelate ring 
since oxygen and nitrogen are harder bases than sulfur.54 
Binuclear tridentate thiosemicarbazone complexes have been prepared from the 
tetranuclear complexes by Vila et a/.72 They cleaved the Pd-Sbrldging bond in the 
tetrameric complex with a variety of tertiary diphosphines including 
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bis(diphenylphosphino)ferrocene using a 1:2 molar ratio of complex to diphosphine 
(Figure 1.9.). In these binuclear complexes (16), one thiosemicarbazone ligand is 
coordinated in a dianionic [C,N,S] manner to each metal center. The two palladium 
metal centers are bridged by the bis(diphenylphosphino) ligand. Mononuclear 
complexes (17) are isolated when a 1:4 stoichiometric ratio is used?5 The 
diphosphine acts as a monodentate ligand via one phosphorus atom. 
168: R1 = 4-Me, R2 = Me, R = H 
16b: R1 = H, R2 = Et, R = H 
16c: R1 = 4-Me, R2 = Me, R = Me 
~ = diphenylphosphlnobutane, dlphenylphosphlnomethane, 
p p 1,1'-bIs( dlphenylphosphlno)ferrocene 
x 
17a: R = Me, X = CI 
17b: R = Et, X= CI 
17e: R= Me, X= Br 
17d: R = Et, X = Br 
Figure 1.8. Structures of binuclear complexes (16) formed by bridging diphenylphosphlno ligands and 
mononuclear complexes (17) with monodentate diphoshlne ligand 
Mononuclear cyclopalladated thiosemicarbazone complexes with a chloride ion as 
ancillary ligand have been directly prepared by reaction of the thiosemicarbazone 
ligand with potassium tetrachloropalladate (18, Figure 1.9.).55 
188: R1 = 4-0Me 
18b: R1 = 3-0Me 
~rNIN~ 
Pd--S 
I I 
I '3 
19 
Figure 1.9. Structures of mononuclear (18) and trinuclear (19) cyclopalladated complexes 
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In the thiosemicarbazone ligand, the N1 nitrogen is substituted with a methyl 
substituent blocking formation of the thiolate which is essential for formation of the 
tetranuclear complex of type 14. The ligand therefore chelates to palladium as a 
singly negative tridentate [C,N,S] donor. A trinuclear paliadium(lI) complex (19) 
prepared by C-H activation of a Sp3 carbon has also been accomplished.76 The imine 
nitrogen and the carbon of the methyl substituent in the ortho position coordinate to 
palladium resulting in the formation of a six-membered chelate ring. 
1.4. Biological Activity of Tridentate Paliadium(lI) Monothiosemicarbazone 
Complexes 
The biological properties of thiosemicarbazones may, in part, be due to their metal 
chelating abilities; complexation to a metal ion within the cell may give rise to the 
actual active species. In addition, complexation to a metal could benefiCially alter the 
bioactivity of thiose mica rbazones. 22 Lipophilicity, which controls the rate of entry into 
the cell, might be modified upon coordination.77 The metal complex may be more 
active than the free ligand and certain long term side effects may decrease or be 
altogether avoided since metal complexes can break down and the metal ion can 
then interact with the organism?8.79 Furthermore, the metal complex could exhibit 
bioactivities not shown by the free thiosemicarbazone ligand and coordination can 
yield a significant reduction in drug resistance.22 
These reasons, together with the established activity of thiosemicarbazones, have 
led to an ever-increasing amount of research into the biological application of their 
metal complexes. For example, metallocene derivatives of titanium and zirconium 
with thiosemicarbazones as well as oxovanadium(IV) complexes of 2-pyridine 
carboxaldehyde have shown activity as antifungal agents;80·81 four and six coordinate 
Ni(lI) thiosemicarbazone complexes have been screened for activity as anti-microbial 
agents.82 
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1.4. 1. Brief Background on Palladium(/I) Complexes as Anticancer Agents 
The antitumoral activity of cis-[diaminedichloroplatinum(II)] (cisplatin or cis-DDP) led 
to the investigation of other metal complexes as anticancer agents since cisplatin, 
while exhibiting good activity, is highly toxic. Neurotoxicity (nerve damage), 
ototoxicity (hearing loss) and nephrotoxicity (kidney damage) are just some of the 
side effects induced by cisplatin.83 Therefore, almost from this initial discovery efforts 
have been made to attain cisplatin's beneficial properties while reducing its toxicity. 
The synthesis and antitumor evaluation of a large number of platinum complexes 
has been accomplished; out of these complexes carboplatin, [diamine(cyclobutane-
1, 1-carboxylato )platinum( II)], has shown activities equivalent to cisplatin but with a 
markedly lower toxicity. 84,85 
In the search for more efficient metal complexes relative to cisplatin, paliadium(lI) 
complexes were amongst the first to be used in clinical trials for the treatment of 
tumors since they exhibit similar aqueous chemistry to those of platinum(lI) and both 
metals have similar chemical properties.86 Platinum and palladium belong to the 
1\ second transition metal series and the +2 and +4 states are their most stable 
~ 
oxidation states. They are classified as soft Lewis acids, forming stronger bonds with 
sulfur and nitrogen donors than oxygen?4 However, paliadium(lI) complexes are 
generally thermodynamically and kinetically less stable than pt(lI) complexes; 
paliadium(lI) complexes undergo ligand exchange reactions and aquation at a rate 
105 times faster than the analogous platinum(ll) complexes.83,86,87 This last property 
explained why the complexes cis-Pd(NH3)CI2 and Pd(1,2-diaminocyclohexane)2CI2 
were found to have lower activity and higher toxicity than its platinum analogues.83 
Since then, interest has moved toward the preparation of Pd(ll) complexes with inert 
ligands such as sulfur donors. It has been suggested that N,S chelates of Pd(ll) are 
better antitumor agents than those of other metals. Nickel(II), copper(lI) and zinc(lI) 
N,S chelate complexes do not have sufficient thermodynamic stability while 
platinum(ll) N,S chelates are kinetically inert. In contrast, palladium(lI) chelates 
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possess the proper lability to transport the metal to DNA, allowing it to interact with 
't 88 I. 
Thiosemicarbazones have arisen as an excellent class of N,S donor ligands in the 
search for better antitumoral palladium(II) complexes. These ligands display 
anticancer activity and it is believed that their mechanism of action is through the 
inhibition of ribonucleotide reductase, an enzyme that catalyzes the conversion of 
ribonucleotides to deoxyribonucleotides, by either coordination to iron in the metal-
bound enzyme or formation of an iron chelate in situ which acts as the active 
inhibitor of the enzyme.89 Their use in conjunction with Pd(II), which is known to 
damage DNA, produces a synergistic effect which could potentially lead to the 
development of more effective cancer chemotherapies. Thus, the study of Pd(ll) 
thiosemicarbazone complexes as anti proliferative agents has emerged as an area of 
great importance. 
1.4.2. Anticancer Activity of Aromatic and Heteroaromatic Derived Tridentate 
Monothiosemicarbazone Pal/adium(l/) Complexes 
The effects of complexes 1d and 2c (Figure 1.10, page 15) and their free ligand on 
DNA synthesis of P388 and L 1210 , mouse lymphocytic leukemia, cell cultures and 
in leukemia P388 bearing mice have been studied.90,91 The free ligand was found to 
exhibit the highest LD1o, the dose required to induce death of 10% of mice used, 
while the complexes exhibited significant reduction of the toxicity, an enhancement 
of cytogenetic damage and a significant increase in the mean survival of the drug 
treated leukemia bearing mice. 
Thiosemicarbazones derived from 2-benzoyl pyridine (20a - 20c) and their tridentate 
[N,N,S] palladium(lJ) complexes (21a - 21c) were screened for cytotoxic activity 
against the MCF-7 (human breast cancer), TK-10 (human renal carcinoma) and 
UACC-62 (human melanoma) cell lines (Table 1.1.).92 
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1d 
~/~y~' N R 
208: R=H 
20b: R= Me 
20c: R= Ph 
S 
15 
N ~ R H ~/NyN, 
I 
~N--Pd--S 
I 
CI 
218: R= H 
21b: R= Me 
21c: R = Ph 
Figure 1.10. Structures of complexes 1d, 2c, 208 - 20c and 218 - 21c 
Table 1.1. Compound concentration that produces 50 % of growth inhibition (GI.§Q) 
and lethal dose (LC§Q) for 50 % of the cells for compounds 20a - 21c 
MCF-7 TK-10 UACC-62 
Compound GI50 (JlM) LC50 (JlM) GI50 (JlM) LC50 (JlM) GI50 (JlM) LC50 (JlM) 
208 2.7 >390.3 4.7 >390.3 5.1 93.3 
20b 0.0007 >369.9 1.8 >369.9 0.2 25.9 
20c <0.003 13.4 9.3 12.9 <0.003 13.8 
218 75.5 146 120.3 217.8 99.5 133.2 
21b 9.5 56.4 27.5 32.6 25 42.6 
21c 6.4 63 24.3 29.6 22.2 33 
The ligand 20c showed the best Giso and LC50 values against all three cell lines. 
Complexes 21a - 21c displayed Giso (50 % growth inhibition) values higher than 
their free ligands indicating lower cytotoxicity. However, complexes 21b and 21c 
exhibited lower LCso values compared to the free ligands against the TK-10 and 
MCF-7 cell lines. This indicates that a lower dose of the complex is needed to kill 
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the cancer cells compared to their corresponding free ligand (20b and 20c) and is 
suggestive of a different mechanism of inhibition for the complexes relative to the 
free ligands. 
The paliadium(lI) complexes (1f and 19) of 2-formyl pyridine thiosemicarbazone 
derivatives were examined for activity against the MCF-7, T24 (bladder cancer) and 
A-549 (non-small cell lung carcinoma) celilines.61 Complex 19 (Figure 1.11.) showed 
better cytotoxicity, IC50 = 3.75 IJM, compared to 1f in the MCF-7 cell line which 
displayed an IC50 value of 83.9IJM. In addition, 1fwas found to be twice as active as 
cisplatin against this cell line. In contrast, both complexes showed similar activities, 
IC50 values of 4.89 and 5 IJM for 1f and 19 respectively, against the T-24 cell line, 
which are Significantly higher than that of cisplatin for this cell line. Complex 1f 
exhibited an IC50 = 12.8 IJM against the A-549 cell line while 19 did not show any 
appreciable activity. 
~~ 
R [.AJ ~(Y·~ ~!---Irs 
Ii ~ L 
1/ j 
/~ 
_N =(s \-
NH2 
5a: R = H. L = PPh3 
5b: R = H. L = 4-picollne 
5c: R = CH3• L = PPh3 
5d: R = CH3• L = 4-plcollne 
1f: R= H 
19: R=CH3 
Figure 1.11.: Structures of paliadium(lI) complexes 1f, 19 , Sa - Sd, Sf and 5g 
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Halder and co-workers reported on the in vitro growth inhibitory effects of 
salicylaldehyde (5a and 5b), 2-hydroxyacetophenone (5c and 5d) and 2-
hydroxynaphthaldehyde (5f and 5g) thiosemicarbazone tridentate [O,N,S] 
paliadium(lI) complexes in two cancer cell lines promyelocytic HL-60 and histiocytic 
lymphoma U-937.64 The results were compared to the human clinical drugs cisplatin, 
BCNU, 5-FU and hydroxyurea (Table 1.2.). 
Table 1.2.: IC~ values (LJM) for 5a-5d. 5f and 5a and selected clinical drugs against 
the HL-60 and U-937 cell lines 
Compound HL-60 U-937 
5a 2.5 4.8 
Sb 16.2 7.3 
5c 0.6 1.3 
5d 7.1 6.6 
Sf 203 231.6 
59 6.5 7.7 
Cisplatin 7.0 3.2 
BCNU 30.5 12.3 
5-FU 266.0 4.7 
Hydroxyurea 204.0 115.0 
In the HL-60 cell line, compounds 5a and 5c, where the ancillary ligand is 
triphenylphosphine, exhibited better activity than the other complexes as well as the 
clinically used drugs. With the exception of 5f, which did not show any appreciable 
activity in either cell line, all of the complexes show activities less than 10 IJM against 
the U-937 cell line and it should be noted that the complex with the lowest ICsa value 
(5c) is a better cell growth inhibitor than cisplatin. Apoptosis experiments were also 
carried out for complexes 5c and 5g. It was found that 5c induced apoptosis to a 
greater extent than cisplatin. 
The phenanthrenequinone thiosemicarbazone complex (12) was evaluated for 
anti proliferative properties in a panel of breast cancer and normal cell Iines.71 It was 
found that the complex was a potent inhibitor of cell growth in the MCF-7/DOX cell 
line which exhibits high resistance against conventional chemotherapeutic agents. It 
Un
ive
rsi
ty 
of 
 C
ap
e T
ow
n
18 
was less effective against the wild-type MCF-7 cell line suggesting that it could be 
used beneficially in the treatment of the resistant tumor cells. The normal cell lines 
were relatively resistant to the toxic effects o~ complex 12 signifying that its growth 
inhibitory effects are specific to tumor cell lines. 
"'>(Y" 
12 
~-id--f 
I I 
22a: R= NH2 
22b: R = NHCHa 
22e: R = N(CH3l2 
22d: R = piperidine 
228: R = azocane 
Figure 1.12.: Structure of complex 12 and tetrameric cyclopalladated p-
isopropylbenzaldehyde thiosemicarbazone derivatives (22a - 22a) 
4 
The cytotoxic activity of tetra nuclear cyclopalladated derivatives of p-
isopropylbenzaldehyde has been reported by Quiroga at al.93-95 The complexes (22a 
- 228) were screened against the HL-60, JURKAT (human leukemia), HeLa (cervix 
epithelial carcinoma), 3T3 (murine fibroblasts), Pam 212 (epidermal keratinocyte) 
and Pam 212-ras (epidermal keratinocyte cells transformed by H-ras oncogene) cell 
lines and their IC50 values are shown in Table 1.3. 
Table 1.3.: ICsa and standard deviation values (UM) for complexes 22a - 228 
HL-60 JURKAT HaLa 3T3 Pam 212- Pam 212 
ras 
22a 28± 1 7±0.3 4±0.1 3±0.2 5±0.4 8±0.3 
22b 22±2 13± 1 86±3 91 ±5 62±2 109±6 
22c 29± 1 25±3 92±3 107 ±4 96±7 134± 7 
22d 10 ± 0.7 9±1 73±3 94± 1 68±2 90±3 
22a 27±2 18 ± 0.7 87±3 104±2 76±2 164±0.8 
The complexes 22a - 228 exhibited activities in the IJM range against all cell lines. 
However, all of them were less active than cisplatin against the HL-60 cell line. The 
complex 22a exhibited better cytotoxicity than cisplatin across all cell lines, with the 
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exception of the HL-60 cell line. It was also noted that while the complexes 22b -
22e did not show appreciable activity overall, their cytotoxic values were better than 
those shown by cisplatin and other clinically used drugs against the JURKAT cell 
line. The Pam 212 and Pam 212-ras cell lines are cisplatin resistant and complexes 
22a, 22b and 22d show moderate activity against Pam 212-ras cells. 
1.5. Application of Paliadium(II) Thlosemicarbazone complexes as catalysts 
or catalyst precursors 
Palladium catalyzed reactions have become essential synthetic tools; their 
applications including the syntheses of polymers,96,97 natural products,98 
agrochemicals99,100 and pharmaceuticals.101 ,102 There are several well-known 
reactions that utilize palladium containing compounds including the Heck, Stille, 
Suzuki and Buchwald-Hartwig cross-couplings. 103,104 In addition, palladium has also 
been used to facilitate hydrogenation, carbonylation, cycloisomerization and even 
pericyclic reactions.103 
The application of thiosemicarbazone paliadium(lI) complexes in catalysis is a fairly 
new area of research. One of the first reports of their catalytic application was 
published in 1998. Pelagatti and co-workers described chemoselective homogenous 
hydrogenation reactions using tridentate [N,N,S] palladium(ll) complexes 21a, 23a, 
23b and 24 (Figure 1.13).105 
218: X = CI 24 
238: X = CH3C02 
23b:X= I 
Figure 1.13.: Structures of complexes 218,238, 23b and 24 used for chemoselective homogenous 
hydrogenation 
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The reactions were carried out at 30·e under atmospheric pressure of hydrogen over 
24 hours with DMF, pyridine or methanol as solvent. Table 1.4. shows the 
hydrogenation data. When the reaction solvent was methanol, the iodo-complex 23b 
was unable to hydrogenate phenyl acetylene, complexes 21 a and 23a showed good 
catalytic activity. Overall, 21a showed the best activity in methanol; it was able to 
hydrogenate phenyl acetylene completely with good selectivity toward styrene. When 
21a was used with DMF or pyridine as solvent its catalytic activity was lower. For 
complex 24 the best results were observed when the reaction was carried out in 
DMF. 
Table 1.4.: Hydrogenation data for phenylacetylene using complexes 21a. 23a. 23b 
and 24 as catalysts8 ,b 
Complex Solvent Phenyl8cetylene (%) Styrene (%) Ethylbenzene (%) 
218 methanol - 92 
238 methanol 
-
44 
23b methanol 100 -
218 dmf 61 37 
24 dmf - 95 
218 pyridine 70 30 
24 pyridine 75 23 
a Catalytic reactions were carned out at 30·C and 1 atm of hydrogen for 24 hours. 
b [phenyl acetylene] = 1.44 x 10-1 mol.dm-3 and [cat] = 1.44 x 10-3 mol.dm-3 
8 
56 
-
2 
5 
-
2 
The paliadium(lI) complex (25) containing a tridentate uninegative [O,N,S] donor 
thiosemicarbazone (Figure 1.14.) was evaluated as a catalyst precursor for the Heck 
reaction of styrene with electron-rich and electron-poor 4-substituted aryl bromides 
(Scheme 1.5.).106 The reactions were carried out in DMF at 150·e for 24 hours using 
sodium acetate as base under an inert atmosphere and in air. Table 1.5. 
summarizes the results of the catalytic studies. High regioselectivity was observed 
for the formation of trans-stilbenes and the presence of cis-stilbenes or 1,1-
diphenylethylenes was either absent or only observed in trace amounts. 
Un
ive
rsi
ty 
of 
 C
ap
e T
ow
n
Scheme 1.5. 
21 
25 Sa 
Figure 1.14.: Structures of complexes 8a and 25 
Pd Complex 25 
NaoAc. DMF. 15O"C. 
24h 
trans - stlbenes + 
1.1-dlphenylethytenes 
Table 1.5.: Heck Reaction of aryl bromides with styrene catalyzed by complex 25 
R Atmosphere ArBr/Pd ratio GCYleid (%) TON 
OMe argon 1000 46 460 
OMe air 1000 12 120 
OMe argon 100000 17 17000 
H argon 1000 54 540 
H air 1000 18 180 
H argon 100000 18 18000 
CHO argon 1000 95 950 
CHO air 1000 94 940 
CHO argon 100000 30 30000 
CHO air 100000 14 14000 
N02 argon 1000 95 950 
N02 air 1000 94 940 
N02 argon 100000 43 43000 
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The catalytic activity depended on the halide substrate, the highest activity was 
observed for the reaction where R = N02. Under argon, a total yield of 46% was 
seen for the highly inactive 4-bromoanisole when the catalyst substrate ratio was 
1: 1 000. Only a yield of 12% was observed for the same catalystsubstate ratio in air. 
For the activated aryl bromides, similar yields were seen in air and under argon 
when the ratio of catalyst substrate was 1:1000. A yield of 18% was observed for 4-
bromobenzaldehyde at very low concentrations of palladium and also when the 
reaction was carried out in air. Overall, while some catalytic activity was exhibited by 
25 when the reaction is carried out in air, better activities were seen under an inert 
atmosphere. This is possibly due to the fact that 25 is thermally stable under 
argon.106 
The catalytic activity of 25 together with its analog 8a was then assessed for the 
Suzuki-Miyaura cross-coupling reaction of aryl bromides and chlorides with phenyl-
boronic acid under aerobic conditions.107 Table 1.6. summarizes the results of the 
study. 
Table 1.6.: Percent conversion of the Suzuki-Miyaura cross-coupling reactions of aryl 
halides with phenyl boronic acid catalYZed by complexes 25 and 8a 
Catalyst ArX(X; R) ArX:Pd ratio % conversion 
25 Br; OMe 1000 40 
8a Br; OMe 1000 53 
25 Br; H 1000 71 
8a Br; H 1000 51 
8a Br; H 1000 71 
25 Br;CN 1000 78 
8a Br;CN 1000 88 
25 Br; CN 100000 13 
8a Br; CN 100000 39 
25 Br; N02 1000 79 
8a Br; N02 1000 83 
25 Br; N02 100000 31 
8a Br; N02 100000 49 
25 CI, H 1000 30 
8a CI, H 1000 26 
25 CI;N02 1000 36 
8a CI; N02 1000 37 
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A stock solution of 25 and 8a in DMF was used at 100·C over 24 hours with Na2C03 
as the base. All the reactions were performed in air and the addition of one 
equivalent of water with respect to the substrates enhanced the catalytic activity. It 
was noted that the catalysts were air stable at 100·C and the deposition of palladium 
black was not observed. Also, the homocoupling of phenylboronic acid to give 
unsubstituted biphenyl was negligible.107 
Conversions ranging from 40 to 71 % were seen for 4-bromoanisole and 
bromobenzene. Conversions of 80 % or higher were observed for 1-bromo-4-
nitrobenzene and 4-bromobenzonitrile. For the cross-coupling reactions where an 
aryl chloride was the substrate low conversions were observed. This could be due to 
the high C-CI bond strength which makes oxidative addition of the substrate across 
the metal centre difficult. 107 
1.6. General Conclusions 
Thiosemicarbazones have emerged as a class of versatile ligands due to their ability 
to adopt several different bonding modes toward a metal. Their established biological 
acitivities has led to a growing interest in the chemistry and application of their 
transition metal complexes. It is important to note that while reports on the use of 
palladium complexes of aryl-derived monothiosemicarbazone complexes as 
biological agents is growing; the study of their tridentate palladium(lI) complexes for 
anticancer activity is still relatively scarce. 
In addition, the application of palladium thiosemicarbazone complexes as catalysts 
or catalyst precursors is still virtually unexplored. From the few reports available their 
ability to catalyze Suzuki-Miyaura coupling reactions in the presence of water and in 
air shows their potential as green catalysts due to their high thermal, air and 
moisture stability and warrants further investigation. 
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1.7. Aims and Objectives of Project 
1.7.1. Aims: 
The overall objective was to prepare a series of paliadium(lI) complexes with 
tridentate thiosemicarbazones and to study their activity as 
(i) antimalarial I anticancer agents 
(ii) catalyst precursors in cross coupling reactions 
1.7.2. Specific Objectives: 
The specific objectives of the research described in this dissertation are: 
• To synthesize and characterize a series of aryl mono-thiosemicarbazone 
ligands as outlined in Scheme 1.6 . 
.-J-~O t) + 
Scheme 1.6. 
Ethanol! Acetic Acid 
Reflux 
• To synthesize tridentate [O,N,S] and [C,N,S] paliadium(lI) complexes of the 
thiosemicarbazone ligands synthesized according to Schemes 1.7. and 1.8. 
~/~yNH:! I' N R-I- # OH S EX:~N/NINH:! __ Pd...:..(L....:.:n:.....CI.::....2!_E...::.~N ___ ... R I I Ethanol! Reflux A h' O-Pdl--S I 
L L = PPh3 or 4-plcoline 
Scheme 1.7. 
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R' 
Scheme 1,8, 
• To evaluate selected Pd(lI) complexes and their corresponding free ligands in 
vitro for anticancer activity against several cell lines and antimalarial activity 
against the P. falciparum strains, W2 (chloroquine-resistant) and 010 
(chloroquine- sensitive). 
• To evaluate the potential activity of selected Pd(lI) complexes as catalyst 
precursors in the Suzuki-Miyaura cross-coupling reaction. 
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Chapter 2: Synthesis and Characterization of Tridentate rO.N.S] 
Monothlosemlcarbazone Paliadium(lI) Complexes 
2.1. Introduction 
Thiosemicarbazones have been shown to exhibit several types of bonding modes, 
as discussed in length in Chapter 1. The most common type of bonding mode for 
salicylaldehyde derived thiosemicarbazones is as tridentate [O,N,S] donors.1-5 There 
have been extensive reports of the complexation of salicylaldehyde 
thiosemicarbazone to different metals including, ruthenium,1 nickel,2 cadmium,6 
mercury,6 platinum,7 cobalt,8 silver 9 and copper.4 
Mononuclear palladium complexes (5, Figure 2.1) can be directly prepared by 
reaction of the ligand with [Pd(L)2CI2] (where L = PPh3 or 4-picoline) in refluxing 
ethanol.5.1o-12 The tetranuclear complex (7a) can also be prepared by reaction of the 
salicylaldehyde thiosemicarbazone with sodium tetrachloropalladate1o. A trimeric 
Pd(lI) complex of 2-hydroxyacetophenone (10d) has also been reported.13 In all of 
these complexes, the ligand bonds to palladium as a dianionic [O,N,S] chelate via 
the thiolate sulfur and the deprotonated phenolic oxygen. 
Coordination of the salicylaldimine thiosemicarbazone ligand to palladium in the 
thione conformation is also possible. 14 Reaction of the ligand with lithium 
tetrachloropalladate in methanol without the use of a base produces a mononuclear 
chloro-palladium complex (8) where the ligand coordinates as an anionic tridentate 
donor. 
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ocrN1M; 
I 
L 
Sa: L=PP~ 
5b: L = 4-picoline 
R 
ocrN1M; 
I I 
! ! 
: : n 
7.: R= H; n=4 
10d: R = CH3, n = 3 
ocr~yNHR 
O-Pd--S 
I 
CI 
Sa: R=H 
8b: R= CH3 
Figure 2.1. Representative structures of certain salicylaldimine thiosemicarbazone palJadium(lJ) 
complexes previously synthesized 
While the preparation of salicylaldehyde thiosemicarbazone metal complexes is well-
documented, it is important to note that the only examples of palladium complexes in 
the literature are for salicylaldehyde derived ligands where the imine carbon is 
substituted with a H atom or methyl group5,10,13 or one hydrogen of the terminal 
nitrogen in the thiourea moiety is substituted with a phenyl or methyl group.12,15 
The preparation of palladium complexes of salicylaldimine thiosemicarbazone 
derivatives with different R-substituents on the phenol ring is, to the best of our 
knowledge, unknown. This chapter reports the synthesis and characterization of 
thiosemicarbazones from aldehydes with functionalized phenol rings and their 
corresponding palladium (II) complexes which will be fully discussed in this chapter. 
2.2. Synthesis of Salicylaldimine Thiosemicarbazones 
2.2.1. General Methods 
The salicylaldimine thiosemicarbazones (26 - 29) were prepared by Schiff base 
condensation of a salicylaldehyde derivative with thiosemicarbazide (Scheme 2.1.).16 
The reaction mixture was refluxed in ethanol or methanol over times varying from 6 
to 18 h. Thiosemicarbazide is only partially soluble in the reaction solvent at ambient 
temperature and heating to reflux facilitates complete dissolution of 
thiosemicarbazide. 
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El'0 H R--I ~ + Methanol I Ethanol .. Reflux 16h-ovemight 
Scheme 2.1. 
E)'/~yN~ I" N R--u-~ s 
26 R = 5-chloro-2-hydroxy 
rI: R = 3-tert. ButyI-2-hydroxy 
28 R = 2-hydroxy-3-methoxy 
29: R = 2-hydroxy 
Upon cooling to room temperature the products precipitate out of solution, with the 
exception of 28 which begins to precipitate while the reaction is still at reflux 
temperature. 
2.2.2. Physical Properties 
Table 2.1. summarizes the physical properties of thiosemicarbazones 26 - 29. The 
thiosemicarbazone ligands were isolated in moderate to good yields as air-stable 
white solids. 
Table 2.1.: Physical Appearance. Yields and Melting Points of Ligands 26 - 29 
Ligand Yield (%) Physical Appearance Melting Point (Oc) 
26 44 White solid 292-295 
27 54 White solid 254-257 
28 94 White solid 216-217 
29 76 White solid 207-209 
Thiosemicarbazones 26, 28 and 29 are known compounds and their melting points 
agree with the Iiterature.17-19 All of the ligands exhibit high thermal stability, with 
melting points generally above 200°C. 
2.2.3. Spectroscopic and Analytical Characterization 
The salicylaldimine thiosemicarbazone ligands (26 - 29) were characterized using 
Nuclear Magnetic Resonance spectroscopy (NMR) and infrared spectroscopy. For 
the known ligands, the proton NMR data corresponds with that of the literature. 14, 18, 19 
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The ligand 27, 3)butyl-2-hydroxy-benzaldehyde thiosemicarbazone, is a new 
compound and additional characterization was carried out in the form of elemental 
analysis and mass spectrometry. 
Nuclear Magnetic Resonance (NMR) Spectroscopy 
Thiosemicarbazones 26 - 29 are insoluble in most organic solvents and NMR 
experiments were run in DMSO-da. Table 2.2. summarizes the proton NMR data 
observed for all of the ligands. The imine proton for all of the ligands resonates as a 
singlet between 8.30 and 8.40 ppm and observation of this peak confirms the 
formation of a Schiff base. 
Ligand 
26 
27 
28 
29 
~/~yNH2 I" N R I # S OH 
Table 2.2.: 1H NMR Data for Thiosemicarbazones 26 - 29 
R H-C=N o-H NJf2 Aromatic N-H(ppm) Protons (ppm) (ppm) (ppm) (ppm) 
5-CI 8.32 10.08 11.33 ...am a 8.01 -6.87 
3-t Sutyl 8.28 10.03 11.29 7.99 7.25 -6.86 
3-0Me 8.39 9.12 11.34 8.04; 7.82 7.50 -6.75 
H 8.35 9.83 11.31 8.04,7.85 
-7.88b 7.85 - 6.86 
R(ppm) 
-
1.40 (tert.-butyl) 
3.79 (OMe) 
-
II • Signal for these protons overlaps With one of the aromatic protons to occur as a singlet. 
'The signal for one terminal amine proton overlaps with the signal of one of the aromatic protons to 
occur as a multiplet. 
The hydroxyl and hydrazinic protons are observed as broad singlets further 
downfield relative to the imine proton. The hydrazinic proton exhibits similar 
resonances for all of the thiosemicarbazones while the hydroxyl proton of the ligand, 
3-methoxy-2-hydroxy thiosemicarbazone (28), occurs slightly more upfield compared 
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to the ligands. The strong electron-donating nature of the methoxy substituent may 
account for this observation. 
Two distinct singlets are observed for the amino, NH2, protons for 28 at 8.04 and 
7.82 ppm. This occurrence of two separate peaks for the amino protons is attributed 
to restricted rotation of the NH2 group around the carbon nitrogen bond axis due to 
delocalisation of the lone pair of electrons of the amino nitrogen (Figure 2.2.).20-22 
II 
Figure 2.2. Depiction of the delocalization of the lone pair of electrons on -NH2 
The amino protons of 29 also show two peaks in the proton NMR spectrum, with one 
peak overlapping with the resonance of one aromatic proton giving rise to a multiplet 
between 7.85 and 7.88 ppm. The aromatic protons of the thiosemicarbazones (26-
29) are observed in the expected region and the methyl protons of the tertiary butyl 
substituent of the aryl ring are observed as a singlet at 1.49 ppm. 
The 13C{1 H} NMR spectra for these ligands show similar shifts for the thione carbon. 
In fact, for ligands 27 - 29 the thione carbon is assigned to a signal seen at 177.8 
ppm and for 26 it is observed at 178.0 ppm. Table 2.3. summarizes the carbon-13 
data for the salicylaldimine thiosemicarbazones prepared. The imine carbon 
resonates between 137.6 and 147.0 ppm for all thiosemicarbazones. The influence 
of the high electron donation into the aromatic ring from the methoxy group of 
thiosemicarbazone 28 is again demonstrated by the upfield resonance of the 
hydroxyl substituted aromatic carbon, at 147.8, relative to the resonances observed 
for 26, 27 and 29. 
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Table 2.3.: 13C{1H} NMR Shifts for Thiosemicarbazones 26 - 29 
Ligand ~=N (ppm) ~=S(ppm) ~H(ppm) ~-..atIc) (ppm) Other (ppm) 
26 137.6 178.0 155.0 130.2,125.4,123.3, 122.2, 
-117.6 
27 147.0 177.8 155.3 136.6,129.3,128.2,119.1, 34.3 (Q-(CH3)a), 118.4 29.2 (C-QH3) 
28 139.8 177.8 147.8 145.9, 120.6, 118.9, 118.2, 55.8 (O-QH3) 112.9 
29 140.0 177.8 156.3 130.9,126.8,120.1,119.1, -116.0 
The chloro-substituted aromatic carbon of 26 is assigned to a peak seen at 123.3 
ppm. For thiosemicarbazone 27, the tertiary butyl substituted aromatic carbon 
resonates at 136.6 ppm. The quaternary carbon of the tertiary butyl group is 
observed at 34.3 ppm and the methyl carbons occur at 29.2 ppm. 
Infrared (/R) Spectroscopy 
Infrared spectra for the salicylaldimine thiosemicarbazones (26 - 29) were run as 
KBr pellets and selected IR absorptions are shown in Table 2.4. The presence of an 
absorption band between 1598 and 1615 cm-1 in the spectrum of each compound 
corresponds to the C=N stretching frequency and confirms formation of the 
thiosemicarbazone product. 
Table 2.4.: Selected IR Absorptions for Thiosemicarbazones 26 - 29 
Ligand N-H (em") O-H (em") C=N (em") C=S (em") 
26 323el1'c, 31658 , 3045d 3405c 1612c 1099c 
27 32488 , 3164-, 3038c 34208 1614- 1148c 
28 33438 , 316~, 3033c 3461- 15988 1060c 
29 33188 , 31738 , 3029b •C 3443c 1615- 1111c 
8 .1) . c • Q strong IntenSity, broad, medium intenSity, weak Intensity 
The absorption band corresponding to the O-H vibration is observed with strong 
intensity for compounds 27 and 28, at 3420 and 3461 cm-1 respectively; with medium 
intensity at 3407 cm-1 for 26 and 3443 cm-1 for 29.23 In the infrared spectrum of each 
compound, three absorption bands are Observed between 3320-3000 cm,1 with 
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varying intensity. The two bands occurring at the higher frequency, ca. 3150 - 3320 
cm-1, in each ligand are assigned to the N-H bond vibrations of the terminal amine 
group. The lower frequency band is therefore due to the hydrazinic N-H bond 
vibration.5,24 
Assignment of the thiocarbonyl (C=S) vibration is sometimes difficult since it has a 
less polar bond than the analogous C=O group and therefore occurs at a lower 
frequency where it is susceptible to coupling effects.25 In addition to this, compounds 
where the C=S group is attached to a nitrogen atom not only show an absorption 
band in the characteristic thione region (1250-1020 cm-1) but several bands may be 
observed between 1563-700 cm-1 due to vibrations involving interaction between the 
C-N and C=S bonds.25 
The stretching frequency of the thione functionality for thiosemicarbazones 26 - 29 
was thus assigned to the strongest band observed in this region of the spectra, 
between 1050 and 1150 cm-1, with the highest frequency band observed for 3-tert.-
butyl-2-hydroxy benzaldehyde thiosemicarbazone (27).22 
Mass Spectrometry and Elemental Analysis 
Since thiosemicarbazones 26, 28 and 29 are known and their proton NMR data and 
melting points agree with their literature values, elemental analysis was only 
determined for thiosemicarbazone 27. The ligand was analysed for C, H, Nand S 
and found to be within acceptable limits to that of the the calculated values. ESI-
mass spectrometry for 3-tbutyl-2-hydroxy-benzaldehyde thiosemicarbazone (27) 
shows a base peak at rnIz 252.1 corresponding to the ligand in its protonated form, 
[M + Ht. 
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2.3. Synthesis of Salicylaldlminato Thlosemicarbazone Pd(lI) Complexes 
2.3.1. General Methods 
The salicylaldimine thiosemicarbazone ligands (26 - 29) were reacted with either, 
dichlorobis(triphenylphosphine )palladium(lI) or dichlorobis( 4-picoline )palladium(ll) 
(Scheme 2.2.)10 to give rise to eight salicylaldiminato thiosemicarbazone palladium 
complexes (26a - 29b), of which six are new complexes (26a - 28a and 26b - 28b). 
26: R = 5-chloro 
27: R = 3-tert. Butyl 
28: R = 3-methoxy 
29: R= H 
Scheme 2.2. 
EtaN I Ethanol I reflux OC-"::::::N/N~NH2 R-; I I ~ O-Pd--S 
I 
L 
268 - 298: L = PPh3 
26b - 29b: L = 4-picoline 
A suspension of the appropriate thiosemicarbazone ligand in dry ethanol is heated to 
60°C to facilitate dissolution of the ligand. Triethylamine and [Pd(LhCI21 (L = PPh3 
or 4-picoline) were then added. The reaction was stirred at reflux over times varying 
from 4 to 6 hours. 
2.3.2. Physical Properties 
The palladium complexes 26a - 29b were isolated as air- and moisture- stable 
orange or yellow solids in low to moderate yields. Table 2.5. summarizes the yields 
and physical properties. All of the complexes show good thermal stability, melting at 
temperatures higher than 180 °C. The complexes where triphenylphosphine is the 
co-ligand (26a -29a) show melting points between 220 and 250 °C. No melting or 
decomposition was observed for 27b even at temperatures greater than 310 °C. 
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Table 2.5.: Summary of Physical Properties of Complexes 26a - 29b 
Complex Yield (%) Physical Appearance Melting Point (OC) 
26a 63 Crystalline yellow solid 221-223 
27a 29 Crystalline orange solid 234-236 
28a 80 Dark orange crystalline solid 241-243 
29a 36 Crystalline orange solid 228-231 
26b 30 Yellow solid decomposition without melting 238-240 
27b 46 Yellow solid No melting or decomposition up to 310 
28b 38 Crystalline orange solid 225-227 
29b 34 Orange Solid decomposition without melting 185-187 
2.3.4. Spectroscopic and Analytical Characterization 
All of the complexes were characterized using NMR and infrared spectroscopy. The 
complexes 26a - 28a and 26b - 28b are new compounds and were further 
characterized using mass spectrometry and elemental analysis. Complexes 29a and 
29b are known and their 1H NMR spectra agree with the Iiterature.10.11 
Nuclear Magnetic Resonance (NMR) Spectroscopy 
The salicylaldiminato thiosemicarbazone Pd(lI) complexes are soluble in most 
organic solvents and NMR experiments were recorded in chloroform-d1. Table 2.6. 
summarizes the proton and phosphorus NMR data for the complexes 26a - 29a; the 
proton NMR data for complexes 26b- 29b are shown in Table 2.7. 
For complexes 26a - 29a, the imine proton resonates as a doublet between 8.13 
and 8.27 ppm. The splitting of this signal is evidence of coordination of the imine 
nitrogen to palladium resulting in long range coupling of the imine proton to the 
phosphorus nucleus of triphenylphosphine.1o.26 A 4J(PH) coupling constant of 
approximately 14.00 Hz further supports phosphorus-proton coupling effects and is 
consistent with coordination of triphenylphosphine trans to the imine nitrogen in 
complexes 26a - 29a26•27 which would be expected if the thiosemicarbazone ligand 
bonds to palladium as a tridentate [O,N,S] donor. 
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e g /NiNH' ~N ~ 
R I c 
O-Pd S 
b I 
PPh3 
Table 2.6.: 1H and 31p{1H} NMR data for complexes 26a - 29a 
3ip iH 
Complex R H-C=N Nth Aromatic Protons (ppm) R PPh3 (ppm) (ppm) (ppm) (ppm) 
8.13 7.23 (d, 4J(H$He) = 2.75, 1H, 
26a 5-CI 25.23 4.74 (8) H.), 7.11 (d, J(HcHb~ = 9.02 
-
7.26-7.55, 
(d, 4JPH = Hz, 1 H, He), 6.59 (d, J(HbHe) 7.66-7.75 
13.62 Hz) = 9.02 Hz, 1 H, Hb) 
8.26 7.20-7.37 (m, 2H, He, H.), 6.57 
3-t Sutyi 7.38-7.48, 27a 24.16 (d,4JPH = 4.59 (8) (t, 3 J(HeHdH.) = 8.82 Hz, 1 H, 0.74 (8) 7.70-7.77 
14.14 Hz) Hd) 
8.24 6.96 (d, 3J(H.Hd) = 8.06 Hz, 
28a 3-0Me 19.67 (d, 4JPH = 4.67 (8) 
1 H, H.), 6.85 (d, 3 J(HeHd) = 3.57 (8) 7.26-7.49, 7.57 Hz, 1H, He), 6.56 (t, 7.49-7.81 
13.87 Hz) 3J(He~He) = 7.79 Hz, 1H, Hd) 
8.27 
29a H 24.97 4.69 (8) 7.28-7.43 (m, 3H, Hb, He, He) - 7.70-7.75, (d, 4JPH = 7.50-7.53 
13.50 Hz) 
S = singlet, d = doublet, t = triplet, m = multiplet 
Disappearance of the signals corresponding to the hydrazinic proton and the 
phenolic proton in the free ligand confirms the nature of coordination of the 
thiosemicarbazone ligand to palladium; as a dianionic (via phenolic oxygen and 
thiolate sulfur) tridentate donor. The terminal amine, NH2, protons are observed as 
Singlets upfield relative to the aromatic protons between 4.50 and 4.75 ppm for 26a -
29a. The aromatic protons of triphenylphosphine and the thiosemicarbazone ligand 
are seen in the expected region of the spectrum. 10, 12 
In the phosphorus NMR spectra, complexes 26a, 27a and 29a exhibit a singlet 
between 24.00 and 26.00 ppm.26 For complex 28a, the phosphorus nucleus 
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resonates further upfield at 19.67 ppm. This shielding is attributed to the electron-
donating nature of the methoxy substituent which would result in greater electron 
density around palladium and hence greater back bonding between palladium and 
phosphorus. 
Table 2.7.: 1H NMR Data for complexes 26b - 29b 
Complex R H-C=N Nth Aromatic Protons R(ppm) 4-Plcoline (ppm) (ppm) (ppm) (ppm) 
7.16-7.448 ,6.94 - 2.44 (CH3), 8.59 (d, 3J(HaH ) 26b 5-CI 7.83 (s) 4.78 (s) 
-
= 6.60 Hz, 2H, H,,}, 7.16-6.96 (m, 2H, Hb, He) 7.44(H )8 
7.32-7.36 (m, 1H, 2.47(CH3), 8.69 (d, 3 J(HaH ) = 
27b 3-t eutyl 7.95 (s) 4.73 (s) He),7.18-7.25
8
, 1.33 (s) 6.50 Hz, 2H, Ha), 7.18-7.25 6.79-6.42 (m, 1 H, (H~)· He) 
7.14-7.31 (m, 1H, 2.43(CH3), 8.70 (d, 3J(HaH ) = 
2ab 3-0Me 7.92 (s) 4.74 (s) He}, 6.95 _7.02
8
, 3.85 (s) 6.60 Hz, 2H, Hal' 6.95 -6.52-6.68 (m, 1 H, 
He) 7.02(H ) 
7.32-7.39 (m, 2H, 
He, He), 7.09 (d, 2.49(CH3), 8.68 (d, 3J(HaH ) = 3 J(HbHe) = 8.95, 1 H, 29b H 7.98 (s) 4.85 (s) Hb), 6.73 (t, - 6.57 Hz, 2H, Ha), 7.29 (d, 
3J(HeHdHe) = 7.38, 3J(H Ha} = 5.96 Hz, 2H, H ) 
1H,~) 
a One aromatic proton of the thlosemlcarbazone ligand overlaps with the signal for the aromatic 
protons beta to nitrogen of the picoline ring; s = singlet, d = doublet, t = triplet, m = multiplet 
In the proton NMR spectra of complexes 26b - 29b (Table 2.7.), the imine proton 
occurs at a lower shift compared to complexes 26a - 29a. This shielding of the 
proton is expected as the 4-picoline CO-ligand is a better sigma-donor towards 
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palladium than triphenylphosphine. The shifts observed for the terminal amine 
protons in 26b ....: 29b are similar to that of 26a - 29a suggesting that there is no 
significant effect on this group from the co-ligand. The protons of the tertiary butyl 
(27b) and methoxy (28b) substituents appear to be slightly more deshielded 
compared to its triphenylphosphine analogues (27a and 28a respectively). 
As with complexes 26a - 29a, the resonances attributed to the phenolic and 
hydrazinic protons in the free ligand are not observed in the spectra of complexes 
26b - 29b supporting coordination of the thiosemicarbazones in the same tridentate 
[O,N,S] manner. The protons of the methyl substituent of the picolyl ring resonate as 
a singlet at ca. 2.40 ppm for 26b - 29b. The signal of one aromatic proton of the 
thiosemicarbazone ligand overlaps with the signal of the protons beta to nitrogen in 
the picolyl ring of the co-ligand to occur as a multiplet in complexes 26b - 29b. The 
protons, Ha of the picolyl ring are seen as a doublet at 8.59 ppm for 26b due to 
coupling to the adjacent proton, H . This pattern is also observed in the spectra of 
the complexes 27b - 29b. 
Table 2.8. lists the resonances observed in the 13C{1H} NMR spectra for all 
complexes, 26a - 29b. The imine carbon of the thiosemicarbazone ligand resonates 
at approximately 170.0 ppm in all of the complexes. This shift is characteristic of 
coordination of the imine nitrogen to palladium leading to a downfield shift of this 
carbon relative to the resonance observed for the free Iigand.15.24.28 The thiolate 
carbon generally occurs between 161.0 and 162.0 ppm for all of the complexes 
except 28a and 28b, where it resonates at 150.9 and 153.8 ppm respectively. It 
seems that in these complexes there is greater shielding of the C-S carbon due to 
the methoxy substituent of the thiosemicarbazone ligand. Overall, the upfield shift of 
the C-S carbon in all complexes compared to the thione carbon of the corresponding 
free ligand is evidence of coordination of sulfur to palladium in the thiolato form since 
shielding of the thiolate carbon is characteristic of this type of bonding.24.29-31 
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Table 2.8.: 13C{1H} data for complexes 26a - 29b 
Complex C=N ~-s ~-O(ppm) Aromatic Carbons (ppm) Other (ppm) (ppm) (ppm) 
26a 171.5 161.2 149.6 128.3-134.7 (PPh3. Ce. Cd and 
-C.). 122.2 (Ct). 118.7 (Cb) 
27a 170.0 162.2 152.3 140.3 (~). 128.0-135.1 (PPh3. 34.8 ~-(CH3)a). 29.4 C •• Cc). 118.0 (~). 114.1 (Ct) «C-{QH3)a) 
=150.se Unassignedb 
128.3-134.8 (PPh3. C.). 126.5 
28a 170.4 (C.). 117.7 (Cd). 115.5 (Ct). 56.6 (O-.QH3) 
113.9 (Cc) 
128.3-134.7 (PPha. Ca. Ce). 
29a 171.0 162.7 150.7 120.7 (Cd). 117.6 (Ct). 114.8 
-
(Cb) 
151.8 (Ca). 132.7 (Cd). 132.3 
26b 172.7 161.1 152.3 (C.). 127.5 (C ).121.9 (Cc). 21.3 (.CH3. Picoline) 
120.5 (Ct). 117.9 (Cb) 
151.7 (Ca). 138.9 (Cb). 132.6 35.2 (.C-(CH3)a). 29.4 
27b 169.8 161.8 152.0 (Cc). 130.3 (C.). 125.9 (C ). (C-{QH3)a. 21.2 (.CH3. 
118.7(~). 114.3(Ct) Picoline) 
151.8 (Ca). 152.2 (Cb). 127.4 56.7 (O-.QH3). 21.2 28b 170.5 153.8 149.0 (C ).126.2 (C.). 125.3 (~). (.CH3. Picoline) 119.1 (Ct). 114.5 (Cc) 
151.0 (Ca). 133.9 (Cc). 133.6 
29b 170.0 162.6 151.6 (C.). 126.3 (C ). 119.9 (Cd). 21.2 (CH3. Picoline) 
118.4 (Ct). 115.1 (Cb) 
8 Signal for the thlolate carbon overlaps with that of the methoxy substituted aromatic carbon to occur 
as a singlet. 
b unable to assign as the signal overlaps with the signals for triphenylphosphine 
The resonances for the aromatic carbons for all complexes are observed in the 
characteristic region of the spectrum. The tbutyl group in 27a and 27b shows similar 
resonances in both complexes and this is also observed for the carbon of the 
methoxy substituent in complexes 28a and 28b. 
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Infrared (lR) Spectroscopy 
Infrared spectra for all of the palladium complexes were recorded as KBr pellets. 
Selected IR absorptions are listed in Table 2.9. for 26a - 29b. 
Table 2.9.: IR absorptions for the imine and amine vibrations for 26a - 29b 
Complex C=N (cm"1) N-H (cm"1) 
268 1605, 1586 3493,3385 
27a 1634,1610 3464,3391 
28a 1642, 1592 3442,3308 
29a 1638,1599 3300,3132 
26b 1622, 1596 3403,3273 
27b 1621,1609,1591 3421,3310 
28b 1621,1603 3428,3351 
29b 1625,1600,1588 3434,3278 
In the infrared spectra for complexes 26a - 29a two bands are observed in the imine 
region, this is consistent with the formation of a new imine bond within the 
thiosemicarbazone ligand upon coordination of sulfur in the thiolate form. The lower 
frequency band, observed between 1610 and 1585 cm"\ is assigned to the imine 
bond coordinated to palladium.13,14,29 When the nitrogen of the imine coordinates to 
the metal, a loss of double bond character occurs due stronger electron donation 
towards the metal, thus this bond will vibrate at a lower frequency. 
For complexes 26b-29b, high frequency bands observed between 1625 and 1620 
cm"1 are assigned to the new imine bond formed. The vibration of the coordinated 
imine for these complexes is harder to assign as the signal for this vibration may 
overlap with the imine vibration of the 4-picolyl ring. In complexes 27b and 29b, 
there are three distinct bands in the imine region and the coordinated imine vibration 
is assigned to the bands observed at 1609 cm"1 for 27b and at 1600 cm"1 for 29b. 
The C=N stretch of the 4-picolyl ring is allocated to the lowest frequency band 
observed. In the spectra of complexes 26b and 28b, the absorption bands observed 
at 1596 cm-1 for 26b and 1603 cm-1 for 28b are slightly broad and this may indicate 
the overlapping of two C=N vibrations resulting in only one absorption band being 
observed. 
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In all of the complexes two absorption bands are observed for the N-H vibrations of 
the terminal amine between 3500 and 3250 cm-1. A third absorption band for the 
hydrazinic N-H bond is not observed and this is consistent with the loss of the 
hydrazinic proton and formation of a new imine bond in the thiosemicarbazone 
ligand. 
Mass Spectrometry and Elemental Analysis 
The formation of the salicylaldiminato thiosemicarbazone Pd(lI) complexes was 
further confirmed using ESI-mass spectrometry run in the positive mode (Table 
2.10.) and elemental analysis. As 29a and 29b are known and NMR data 
corresponded to the literature,10,11 these complexes were not submitted for further 
characterization. 
Table 2.10.: Mass Spectral Results for Complexes 28a - 28b 
Complex Calculated Molar Molecular Assignment Mass (g/mol) Fragment 
26a 596.37 597 [M+Hr 
27a 618.04 617 [M-Hr 
28a 591.96 591 [M-Hr 
26b 427.22 429 [M+2Ht+ 
27b 448.88 449 [M+Hr 
28b 422.80 423 [M+Hr 
All of the complexes showed a base peak corresponding to the calculated molar 
mass with either loss or gain of a proton. Elemental analysis results are in within 
acceptable limits compared to the calculated values for all complexes. 
2.4. X-ray Crystallography 
Single crystals suitable for X-ray diffraction of the Pd(lI) complexes 28a - 28a were 
grown by slow-evaporation of a 1: 1 OCM-hexane or COCh-hexane solvent system. 
Table 2.11. summarizes the crystal data for each molecular structure and Table 
2.12. lists selected bond lengths and angles of the molecular structures. 
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Table 2.11.: Crystallographic Data of Complexes 26a - 27a 
26a 27a 28a 
Empirical formula C27H23ChN30PPdS C32H30CleD2N30PPdS C27H24N302PPdS 
Empirical Weight 681.26 858.75 591.92 
Crystal size 0.20 x 0.14 x 0.08 mm 0.18 x 0.14 x 0.14 mm 0.12xO.11 xO.09mm 
Crystal system, space Monoclinic, P24c Monoclinic, P24n Monoclinic, C21c group 
8 14.7145(4) A 10.1900(2) A 33.3399(7) A 
b 8.0414(1) A 20.5408(4) A 10.3708(2) A 
c 24.3591(6) A 17.9344(3) A 14.9613(2) A 
alpha goo goo goo 
beta 101.151 0 102.5430 102.09100 
gamma 900 goo 900 
Volume 2827.88(11)A3 3664.27(12)A 3 5058.28(16) A3 
z 4 4 8 
Calculated density 1.600 Mg/m3 1.557 Mg/m3 1.555 Mg/m3 
F(OOO) 1368 1728 2400 
R Indices (aU data) R1 = 0.0528, wR2 = R1 = 0.0476, wR2 = R1 = 0.0362, wR2 = 0.0883 0.0887 0.0628 
Complex 26a (Fig. 2.2.) crystallized with a monoclinic system and space group 
P21/C. There is one molecule of dichloromethane solvent included in the structure 
per complex molecule in 26a and two chloroform molecules included in the crystal 
per complex molecule for 27a. Figures 2.3. and 2.4. show the molecular structures of 
complexes 27a and 28a respectively. In a" of the complexes, the thiosemicarbazone 
ligand coordinates to palladium in the expected tridentate fashion, via the phenolate 
oxygen, imine nitrogen and thiolate sulfur forming five- and six-membered chelate 
rings with the metal. The fourth coordination site is occupied by the 
triphenylphosphine co-ligand trans to the imine nitrogen. 
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FigoJ re 2.2 : Molecular structu re of compklx 2h with elli ps~ daI moOOl Of probabl ity 
levEl! . 40%. Tr.e sol"",,! mdeoula CH,CIo is excJLJd ed. 
Figure 2.3 .. MoiIIcular w..o:lure of complex 21, v.tth ellipsoidal model 01 probab)iIy 
level = 40%. All H eta omitled to , da r~)' Two soIve nl molecu les CDC!;,!!,,! 8I!dudod 
Fig.ne 2 ..... MoIewI., 5truclure of com~~ 28a wolh elliP!oOidai moOOl oj prob3blily 
,oye!- 40%. 
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The bite angles formed between the metal and the coordinated ligands show that in 
each complex there is a slightly distorted square-planar arrangement around the 
metal. All of the bite angles around the metal in each complex are consistent with 
those observed for similar complexes.10-12 The bite angle that shows the least 
deviation from 90° is the P(1)-Pd(1)-O(1); 89.41(7) for 26a, 90.07(6) for 27a and 
90.43(5) for 28a. The trans angles O(1)-Pd(1)-S(1) and N(3)-Pd(1)-P(1) are close to 
linearity in all of the molecular structures with 26a showing the least deviation from 
180°. 
Table 2.12.: Selected Bond Lengths and Angles for Complexes 26a - 28a 
26a 27a 28a 
Pd(1)-S(1) 2.2432(8) A 2.2426(8) A 2.2478(6) A 
Pd(1)-P(1) 2.2833(8) A 2.2782(8) A 2.2779(6) A 
Pd(1)-N(3) 2.028(3) A 2.012(2) A 2.0204(19) A 
Pd(1)-O(1) 2.014(2) A 2.033(2) A 2.0164(16) A 
C(1)-8(1) 1.754(3) A 1.754(3) A 1.751(3) A 
C(1)-N(2) 1.303(4) A 1.304(4) A 1.291(3) A 
C(2)-N(3) 1.294(4) A 1.293(4) A 1.294(3) A 
N(3)-Pd(1)-S(1) 84.16(8)· 84.52(7)· 84.09(6)" 
N(3)-Pd(1)-P(1) 177.29(8) 175.78(7) 175.91(6) 
N(3)-Pd(1)-O(1) 93.03(10)" 92.15(9)" 93.15(7)· 
P( 1 )-Pd( 1)-S( 1 ) 93.41(3)· 93.56(3)· 92.27(2)· 
O( 1 )-Pd(1 )-8(1) 177.14(7)· 174.07(6) 176.51(5) 
P( 1 )-Pd( 1)-0( 1) 89.41(7)· 90.07(6)· 90.43(5)· 
Inspection of the bond angles formed between the metal and the coordinated atoms 
show that they are consistent with analogous complexes.10,11 The Pd(1)-N(3) bond 
distance observed in 26a and 28a are slightly longer than that of 27a. This suggests 
there may be greater trans influence exerted by the triphenylphosphine ligand in 
these two complexes.12 
The C( 1 )-S( 1) bond has a length of approximately 1.75 A for all three complexes, 
closer to the expected bond length of a typical C-S single bond (1.82 A) than that of 
a C=S double bond (1.56 A),32 confirming that sulfur coordinates to palladium in the 
thiolate form.33 Further evidence of this is obtained from the bond distances 
observed for the C(1 )-N(2) bond. The approximate bond length of 1.30 A in all of the 
molecular structures is similar to that of the C(2)-N(3) imine bond, indicating 
increased double bond character and formation of a new double bond between 
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carbon and nitrogen in the thiosemicarbazone ligand upon coordination to 
palladium. 10, 15,34 
2.6. Conclusion 
Salicylaldimine thiosemicarbazones (26 - 29) were prepared by Schiff-base 
condensation reactions of thiosemicarbazide and the appropriate salicylaldehyde 
derivative and isolated as air stable solids. These ligands were reacted with 
dichlorobis(triphenylphosphine )paliadium(ll) and dichlorobis( 4-picoline )paliadium(ll) 
to yield eight salicylaldiminato thiosemicarbazone Pd(lI) complexes (26a-29b), six of 
which are new compounds. 
Spectroscopic characterization of these complexes support coordination of 
thiosemicarbazone as a dianionic tridentate [O,N,S] donor to palladium. This was 
further supported by the molecular structures of 26a - 28a which were ascertained 
using single crystal X-ray diffraction methods. 
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Chapter 3: Towards the Synthesis of Tridentate rC.N.S] 
Monothiosemicarbazone Paliadium(lI) Complexes 
3.1. Introduction 
Aryl-derived monothiosemicarbazones are capable of coordinating to palladium as 
[C,N,S] tridentate donors via sulfur, imine nitrogen and the C-H activated aromatic 
ortho-carbon.1 These types of Pd(lI) compounds are also known as cyclopalladated 
or ortho-palladated complexes. Tetranuclear thiosemicarbazone paliadium(lI) 
complexes have been reported (14, Figure 3.1.).2-6 The thiosemicarbazone ligand 
forms two fused rings with the metal center and Pd-Sbridglng coordination bonds give 
rise to a Pd4S4 core. 
E:C~N~-Rl_1 I I 
~ IS 
L 
14 15: L = tertiary phosphine 
18 
Figure 3.1.: Examples of the variety of palladium complexes prepared from aryl mono-
thiosemicarbazones 
When the tetra nuclear complex is reacted with a nucleophile such as a tertiary 
phosphine the palladium-sulfur bridging bond is cleaved, yielding a mononuclear 
ortho-palladated complex (15). Substitution of the hydrazinic nitrogen (N1) with a 
methyl group hinders formation of the thiolate and the ligand acts as a uninegative 
[C,N,S] donor yielding a mononuclear complex (18)2 since the thiolate sulfur is 
fundamental for the formation of the tetranuclear structure. 
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In this chapter, the synthesis and characterization of five aryl mono-
thiosemicarbazones and their corresponding palladium(II) complexes will be 
presented. All of the ligands have previously been synthesized?,8 In addition they 
have shown activity as inhibitors of the Trypanosoma cruz; cysteine protease 
cruzain.7 This established bioactivity has led to an interest in the preparation and 
application of their palladium(II) complexes as possible biological agents. 
Cyclopalladation of these thiosemicarbazones by C-H activation of the orlho-carbon 
was undertaken and proved successful for two of the ligands. The remaining three 
thiosemicarbazones exhibited a different coordination mode toward palladium and 
the results are fully discussed. 
3.2. Preparation of Aryl Monothiosemicarbazones 
3.2.1. General Methods 
Ligands 30 - 34 (Scheme 3.1.) were prepared using the same method of preparation 
as that of thiosemicarbazone ligands 26 - 29, outlined in Chapter 2 (Section 2.2.1.). 
The appropriate aryl aldehyde or ketone was condensed with thiosemicarbazide in 
methanol or ethanol. Acetic acid was added for those condensation reactions where 
a ketonic starting material was used, since the carbonyl functional group is generally 
less reactive than its aldehyde analogue .. 
d'0. R I -I-~ + Methanol I Ethanol Reflux 16h-ovemight 
Scheme 3.1. 
~R~/~yNH2 I '" N R---ir~ 5 
30: R = 3,4-dichloro; R' = CH2CH3 
31: R = 3,4-dlchloro; R' = CH3 
32: R = 3,4-dichloro; R' = H 
33: R = 3,5-bis(trifluoromethyl); R' = CH3 
34: R = 3,5-bis(trifluoromethyl); R' = H 
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3.2.2. Physical Properties 
Ligands 30 - 34 were isolated as white solids in moderate to low yields. Table 3.1. 
lists their physical appearance and melting points which correspond to the 
Iiterature.7,8 
Table 3.1.: Physical appearance. yields and melting points for 30 - 34 
Ligand R R' Yield (%) Physical Melting Point (OC) 
Appearance 
30 3,4-dichloro CH2CH3 21 White solid 188-190 
31 3,4-dichloro CH3 35 White solid 191-192 
32 3,4-dichloro H 13 White solid 195-198 
33 3,5-bis(trifluoromethyl) CH3 41 White solid decomp.240-241 
34 3,5-bis(trifluoromethyl) H 27 White solid 225-227 
All of the ligands exhibit high thermal stability with compounds 30 - 32 and 34 
melting at temperatures greater than 180°C; ligand 33 decomposes between 240 -
241 °C. The ligands show poor solubility in most common organic solvents. They 
were found to be soluble in dimethyl sulfoxide (OMSO) as well as water. 
3.2.3. Spectroscopic Characteriza ion 
Since ligands 30 - 34 are known compounds, they were characterized using only 
Nuclear Magnetic Resonance (NMR) and infrared (IR) spectroscopies. The data 
obtained corresponds to the literature values and confirm the integrity of these 
molecules.7,8 
Nuclear Magnetic Resonance (NMR) Spectroscopy 
1H and 13C{1H} NMR as well as 19F{1H} NMR spectra were recorded for ligands 33 
and 34. Table 3.2. summarizes proton (30 - 34) and fluorine (33 and 34) NMR data. 
For all of the ligands, the hydrazinic proton is observed as a singlet at downfield-
resonances between 10 - 12 ppm and the terminal amine protons occur between 
8.10 and 8.50 ppm. 
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The imine proton of ligand 32 resonates at a similar frequency as the terminal amine 
protons and the signals for these three protons overlap to appear as a singlet. 
Similar to ligands 28 and 29, discussed in Chapter 2 (Section 2.2.3), ligands 30 and 
34 show two distinct singlets for the -NH2 protons. This observation is also attributed 
to restricted rotation of the -NH2 group around the carbon nitrogen bond axis due to 
the delocalisation of the lone pair of electrons of the amino nitrogen.9-11 
R' 
Table 3.2.: 1H and 19FCHl NMR Data for Ligands 30 - 34 
1H 19F 
Ligand R R' H-C=N N-H Nth Aromatic protons Other CD (ppm) (ppm) (ppm) (ppm) (ppm) 
8.31 8.23 (8, Ha), 7.86 (dd, 2.86 (q, 
30 3,4-dlchloro Et 10.36 (8), 4J(HeHa) = 2.80, 3J{HeHd) CH2), - (8) = 8.55 Hz, He), 7.61 (d, 0.98 (t, -8.13(8) 
3 J(HdHe) = 8.54 Hz, Hd) CH3) 
10.20 
3 8.26 (8, Ha), 7.!..90(d, 
2.33 (8, 31 3,4-dlchloro Me 8.13(8) J(HdHe) = 8.52 Hz, HiI), 
- (8) 
. 7.66 (d, 3 J(HeHd) = 8.52 CH3) -
Hz, He) 
7.98 (8, Ha), 7.71 (d, 
32 3,4-dlchloro H =8.21 11.51 =8.21 3 J(HdHe) = 8.37 Hz, Hd), (8) (8) (8) 7.63 (d, 3J{HeHd) = 8.33 - -
Hz, He) 
3,5- 10.33 8.52 (8, 2H, Ha, He), 8.05 -61.59 33 bls(trlfluoro Me 
- (8) 8.33 (8) (8, 1H, He) 2.34 (8) (8) 
-methyl) 
3,5- 11.68 8.43 8.52 (8, 2H, Ha, He), 8.03 -61.74 34 bls(trlfluoro H 8.16 (8) (8) (8), (8, 1H, He) - (8) 
-methyl) 8.34 (8) 
8 = Singlet, d = doublet, dd = doublet of doublets, t = triplet and q = quartet 
The imine proton for ligand 34 resonates at 8.16 ppm as a singlet. For ligands 30 -
32, where the R substituents on the aryl ring are chlorido groups in the 3 and 4 
positions, the three aromatic protons show distinct signals between 7.60 and 8.30 
ppm. The furthest upfield resonance (ca. 7.60 ppm) of the aromatic protons is 
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assigned to the proton in the 5-position (He) and the proton (Ha) bonded to the C-2 
carbon of the ring is assigned to the most downfield shift. 
For thiosemicarbazones 33 and 34, where trifluoromethyl groups are bonded in the 3 
and 5 positions of the aryl ring, only two singlets are observed for the aromatic 
protons since two of the protons are chemically equivalent. For both ligands, the 
protons Ha and He occur at 8.52 ppm as a singlet. The 19FCH} NMR spectrum of 
ligands 33 and 34 show a singlet at -61.59 and -61.74 ppm respectively, evidence 
that only one product is isolated. 
Table 3.3. summarises the 13CCH} NMR data for thiosemicarbazones 30 - 34. For 
all of the ligands, the thione carbon is observed at a similar shift (ca. 179.0 ppm) and 
the imine carbon exhibits a peak between 139.0 and 149.0 ppm. 
Table 3.3.: 13C {1Hl NMR Shifts Observed for Ligands 30 - 34 
Ligand .c=N (ppm) .c=S (ppm) ~.rom.uc) (ppm) Other (ppm) 
30 149.3 179.2 136.9 (Ct). 131.5 (Cc). 131.4 (Cb). 130.2 18.9 (QH2). 10.5 (QH3) (Ca). 128.2 (Cd). 126.7 (Ca) 
31 145.2 179.1 138.2 (Ct). 131.5 (Cc). 131.2 (Cb). 130.0 13.6 (QH3) (Cd). 128.0 (Ca). 126.5 (Ca) 
'-- 134.9 (Cc). 131.7 (Cb). 131.6 (Cd. 130.5 32 139.4 178.3 (Cd). 128.0 (Ca). 127.4 (Ca) -
33 145.9 180.1 141.2 (Ct). 131.3 (Cb• Cd). 127.9 (Ca. 122.7 (QF3). 14.9 (QH3) Ca), 125.4 (Cc) 
34 139.7 179.4 138.0 (Ct). 132.0 (Cb• Cd). 128.5 (Ca. 123.0 (QF3) Ca). 125.4 (Cc) 
The aromatic carbons of 30 - 32 show six distinct peaks between 130.0 and 126.0 
ppm. For ligands 33 and 34 the trifluoromethyl substituted carbons are observed at 
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131.3 and 132.0 ppm respectively. The ortho carbons occur at ca.128 ppm and the 
fluorine substituted carbons show a peak at approximately 123 ppm. The methyl 
carbon of the imine subtituents for ligands 31 and 33 are observed at 13.6 and 14.9 
ppm respectively, while the -CHr carbon of the ethyl substituent for ligand 30 
resonates at 18.9 ppm. 
Infrared (lR) Spectroscopy 
Infrared spectra for thiosemicarbazones 30 - 34 were recorded as KBr pellets and 
selected IR absorptions are shown in Table 3.4. 
Table 3.4.: Selected IR Absorptions for Ligands 30 - 34 
Ligand N.H (cmo1) C=N (cmo1) C=S (cmo1) 
30 3389c, 3254c, 3174c 1595C 10548 
31 3421 8 , 3181 c, 3141 c 15948 1091 8 
32 339-r:, 3256c, 31568 15978 1130c 
33 3436c, 32578 , 31638 16028 1118c 
34 3451 8 ,33038 ,31748 1601 8 11528 
8 •• D • C . a strong IntenSity, broad, medium Intensity, weak Intensity 
Three absorption bands are observed for the N-H vibrations in each ligand and is 
consistent with the three N-H bonds present.12 The imine bond shows an absorption 
band in the expected region of the spectrum between 1590 and 1605 cmo1 • The C=S 
vibration for each thiosemicarbazone is assigned to a band observed between 1050 
and 1155 cmo1 • 
3.3. Preparation of Tetrameric and Dimerlc Paliadium(lI) Complexes 
3.3.1 General Methods 
The cyclopalladation of 3,4-dichloropropiophenone and 3,4-dichloroacetophenone 
thiosemicarbazone (30 and 31 respectively) was achieved by treatment of each 
ligand with a suspension of potassium tetrachloropalladate in deoxygenated ethanol 
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and water (Scheme 3.2.).3 The reaction was stirred at ambient temperature under 
argon for 48 hours and the cyclopalladated tetrameric complexes (30a and 31a) 
were isolated by vacuum filtration and washed with ethanol. 
450C 
Scheme 3.2. 
R' 
8C~N"""""'N~NH2 ~ I I I A Pd--S .&7 I I I I 
I I 
I I 
• I 
! 4 
30a: R = 3,4-dichloro; R' = CH2CH3 
31a: R = 3,4-dichloro; R' = CH3 
R' 
R d:1 ~ ~N ........... NINH2 
# \i-s ~- \ 
~_CI 
2 
32a: R = 3,4-dichloro; R' = H 
33a: R = 3,5-bis(trifluoromethyl); R' = CH3 
348: R = 3,5-bis(trifluoromethyl); R' = H 
When this synthetic method was extended to ligands 32 - 34, the expected 
tetrameric ortho-palladated complex was not isolated. Spectroscopic characterization 
of the crude solids isolated showed a mixture of possible decomposition prod ucts as 
well as unreacted ligand. 
Initially, it was thought that the use of water either caused the cyclometallated 
product to decompose or hindered formation of the desired tridentate 
thiosemicarbazone Pd(ll) complex. In addition, reaction at ambient temperature may 
have been too mild to allow C-H activation of the ortho-carbon. For these reasons, 
the synthetic method was modified (Scheme 3.2.). Thiosemicarbazones 32 - 34 
were reacted with potassium tetrachloropalladate in dry, deoxygenated ethanol at 45 
°C over 24 hours under argon. However, the complexes isolated are chloro-bridged 
dimers where the thiosemicarbazone ligand coordinates to palladium as a 
uninegative [N,S] bidentate donor (32a - 34a). Quiroga et al have previously 
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reported the synthesis and characterization of thiosemicarbazone paliadium(lI) 
complexes of this type using a similar reaction method.13 Hence, based on their 
structural characterizations as well as subsequent reactions discussed in Section 
3.4., we believe the proposed structures of complexes 32a - 34a to be correct. 
For the ligand 3,4-dichloro-benzaldehyde thiosemicarbazone (32), the reduced steric 
effect of the imine hydrogen may explain why C-H activation of the ortho-carbon 
does not occur. Lobana and co-workers found that cyclometallation of the aromatic 
ring only occurred when a bulky substituent, such as a methyl, was present on the 
imine carbon of the thiosemicarbazone ligand instead of hydrogen.14 They 
rationalized that steric interaction between the bulky substituent and the aromatic 
ring pushed the ring closer to the metal thereby allowing cyclometallation to occur 
(Figure 3.2.). When the substituent is hydrogen, there is reduced steric interaction 
and the ring is not close enough to the metal for ortho-palladation to occur. 
Sterie interaction 
~ H 1)~ H 
~ ~/N~NH2 I N ~I 
# '-"";'\\d-S H \ 
pp~ 
oxidative insertion of Pd Into activated C-H bond 
Figure 3.2.: Proposed rationalization for C-H activation of ortho-carbon in aryl 
thiosemicarbazone ligands 14 
This argument seems valid when the general mechanism of C-H activation is taken 
into account. Cyclopalladation via C-H activation is initiated by coordination of the 
nitrogen atom to the metal center. This is followed by the dissociation of a ligand 
from the metal complex to yield a highly reactive intermediate. This intermediate 
activates the C-H bond of the ligand in a kinetically controlled electrophilic step that 
shows a preference for the formation of a five-membered ring and attack on an 
aromatic ring thereby forming the cyclometallated product.15 
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In the case of ligands 33 and 34, the presence of the bulky trifluoromethyl substituent 
in the 3 and 5 positions on the aromatic ring may hinder the oxidative insertion of 
palladium into the ortho C-H bond. It is also possible that the cyclometallated product 
may not be stable and decomposes before it is isolated, the strongly electron-
withdrawing nature of the trifluoromethyl groups may weaken the ortho C-H bond 
making it unstable. 
3.3.2. Physical Properties 
The Pd(lI) complexes 30a - 34a were isolated as yellow or orange solids in 
moderate to low yields (Table 3.5.). The tetrameric complexes 30a and 31a exhibit 
high thermal stability; only decomposing at temperatures greater than 300°C. 
Table 3.5.: Physical Appearance. Yields and Melting points for 30a - 34a 
Complex Yield (%) Physical Appearance Melting Point 
30a 15 Yellow Solid decamp. 309-311 °C 
31a 18 Yellow Solid decamp. 307-309 OC 
32a 67(crude) orange solid -
33a 48 (crude) orange solid -
34a 63 (crude) orange solid -
The crude dimeric complexes 32a - 34a were found to be insoluble in most organic 
solvents as well as water even at elevated temperatures, therefore purification by-
recrystallisation was not possible. Thin layer chromatography (TLC) was used to 
determine a suitable solvent system for separation and purification of the products. 
Satisfactory separation of the bands was not achieved and only a crude yield can be 
reported for these compounds. Complexes 32a - 34a were therefore used in 
subsequent reactions (Section 3.4.) without further purification. 
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3.3.3. Spectroscopic and Analytical Characterization 
Complexes 30a - 34a are new compounds and were characterized using NMR and 
IR spectroscopies, mass spectrometry and elemental analysis (30a and 31a). The 
complexes 33a and 34a were only characterized using proton and fluorine NMR and 
IR spectroscopy. The crude nature of these compounds meant that carbon-13 NMR 
spectra and elemental analysis could not be determined. 
Nuclear Magnetic Resonance (NMR) Spectroscopy 
Proton and carbon NMR spectra were recorded for complexes 30a - 32a. The crude 
nature as well as low solubility of the palladium(ll) complexes 33a and 34a meant 
that the 13C{1H} NMR spectra obtained was unassignable and thus only their 19F{1H} 
and proton NMR data are reported. Table 3.6. lists the proton NMR data for 
complexes 30a - 34a. 
For all of the complexes, the amino protons are observed between 7.05 and 7.30 
ppm as a singlet. For complexes 30a and 31 a, only two singlets were observed in 
the aromatic region and were integrated for one proton each. This supports 
palladation of the ortho-carbon upon loss of the proton. For 32a, three protons are 
observed in the aromatic region, between 7.63 - 8.24 ppm, correlating to no C-H 
bond activation of the ortho-carbon. 
R' 
.a:N/N~"" R_I- I I 
I A Pd--S 
c ~a : I 
b : I 
; ! 4 
, : 
308 and 318 
328-348 
Figure 3.3. Structures of complexes 30a - 34a 
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Table 3.6.: 1H and 19F{1Hl NMR data for complexes 30a - 34a 
1H 19F 
Complex R R' Aromatic protons NJ:b Other C& (ppm) (ppm) (ppm) (ppm) 
30a 3,4-dichloro Et 7.36 (8, Hb), 6.68 (8, 7.11 2.48 (CI::b), 
-He) 0.925(C1::b) 
31a 3,4-dichloro Me 7.36 (8, Hb), 6.71 (8, He) 7.17 1.99 (C1::b) -
8.24 (8, He), 7.91 (dd, 
4J(HaHe) = 1.86, 8.52 32a 3,4-dichloro H 3 J(HaHb) = 8.53 Hz, 7.08 (tl-C=N) -Ha), 7.63 (d, 3J(HbHa) = 
8.50 Hz, Hb) 
33a 3,5-bi8(trifluoro- Me 8.53 (8, Ha, He), 8.19 (8, 7.19 1.81 (C1::b) -61.59 methyl) He) 
34a 3,5-bi8(trifluoro- H 8.71 (8, 2H, Ha, He), 7.31 8.45 -61.69 methyl) 8.12 (8, 1H, He) (tl-C=N) 
8 = singlet, d = doublet, dd = doublet of doublets 
The imine proton of 32a is observed downfield, at 8.52 ppm, relative to its free ligand 
32. This deshielding effect is attributed to coordination of the imine nitrogen to 
palladium and supports the formation of an exo-cycle (where the imine functionality 
is not included within the chelate ring) between the ligand and the metal.16 Studies of 
the effect of endo vs exo ring formation showed that when the imine functionality is 
included within the chelate ring (endo) there was an upfield shift of the imine proton; 
the opposite effect is observed for the exo_ring.16-18 The imine proton of complex 34a 
also exhibits this downfield shift compared to its free ligand (34). 
The absence of a signal corresponding to the hydrazinic proton in the proton spectra 
for 30a - 34a corroborates coordination of sulfur to palladium in the thiolato form and 
formation of a new imine bond upon deprotonation of the hydrazinic nitrogen.2,13 
Figure 3.4. shows the proton and fluorine NMR spectra for complex 33a. A less 
intense peak adjacent to each peak attributed to the major product is evident 
suggesting an isomeric mixture of compounds. Additionally, the fluorine NMR 
spectrum shows two singlets confirming the presence of another compound. A 
similar pattern was observed for 34a. Separation of the mixture was not achieved 
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and so only the most prominent peaks were integrated and assigned. supporting the 
proposed dimeric structures of 33<1 and 34<1. 
..,," 
... 
...... J' ••••••• 
Figure 3.4 : 'H and "F{' H} (inset) NMR spectra for complex 33a 
The nC{'H} NMR spectra were assigned only for compl xes 30a - 328 and the data 
are summarized in Table 3.7. Complexes 33a and 34a were crude complexes and 
their carbon-13 NMR spectra could oot be resolved. 
Table 3.7 : 13C{'H} NMR Data for Complexes 30a - 32a 
Complex (~=~l 0·' hlPm) ~I"""""';') (ppm) Other (ppm) 
'"' 
168.1 170.8 165.5 (C, ). 149.4 (C,), 134.2 (C,), 211 (CH, j, 12.0 130.3 (C, ), 126.9, (C.), 126.3 (C,) (CH,) 
--,------
165,1 (C, ), 150.7 (e,). 1339
B 
~~!; 
"" 
166,1 167.7 129.9 (C, ), 126.8 (C, ), 12!3.6 C 14.3 
, 132.6 Ie;,;;, 132\ (~:;, 132_~ (;2~' 
"" 
169.3 , 179,7 131.4(C ,130.1 C ,130.7 C .. , 
CoordinatIOn of the Imine nitrogen to palladium IS further supported by the 
assignment of the imine carbon for all complexes to a peak between 166.0 and 
168.0 ppm. a downfield shift relative to the free ligands (30 - 32) where the C=-N 
carbon peak occurs between 140,0 - 149.0 ppm. This is in accordance with 
resonances observed for similar complexes.2 .1~ An upfield shift of approximately 10 
ppm of the C-S carbon in the complex compared to the thione carbon of the free 
ligand confirms coordination of sulfur in the thiolato formation. 19 
For complexes 30a and 31a, the ortho-carbon shows a large shift from 
approximately 128.0 ppm in the free ligand to 165.0 ppm. This extreme deshielding 
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of the carbon nucleus is characteristic of palladation of the ortho-carbon and 
substantiates formation of the cyclopalladated complexes 30a and 31a.17.19 A similar 
downfield shift of the ortho-carbon is not observed for 32a, further evidence that C-H 
activation of the ortho-carbon did not occur. All other aromatic carbons are observed 
within the characteristic region of the spectrum for 30a - 32a. 
Infrared (IR) Spectroscopy 
Table 3.B. shows selected IR absorption frequencies for complexes 30a - 34a. Only 
two absorption bands are observed in the N-H region of the spectrum for all 
complexes, except for 32a which shows a strong, broad band possibly due to 
overlapping of the two N-H vibrational bands, corresponding to loss of the hydrazinic 
proton and formation of an imine bond. 
Table 3.B.: Selected IR absorptions for 30a - 34a 
Complex N-H (crn"l) C=N (em") 
30a 3459<>, 3376c 1595, 1561 
31a 3442\ 3369<> 1597,1560 
32a 34368 ,D 1615, 1560 
33a 3409", 3308" 1614, 1579 
34a 3469", 3279" 1618, 1582 
8 • • D • C • g strong IntenSity, broad, medium Intensity, weak Intensity 
The formation of the second imine bond is further supported by the observation of 
two absorption bands between 1560 and 1620 cm"1. The lower frequency band is 
assigned to the palladium coordinated imine nitrogen. A shift to lower frequency 
compared to the free ligand is attributed to the loss of double bond character upon 
coordination of the nitrogen to the metal. The higher frequency band is hence 
assigned to the stretching vibration of the newly formed C=N and points to the 
formation of the thiolate. 
Assignment of the thiolate (C-S) bond vibration was not attempted as it occurs within 
a region of the spectrum (700-600 cm"1) where several other bond vibrational bands 
are observed and thus could not be assigned with certainty. 
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3.4. Preparation of Monomeric Paliadium(lI) Complexes 
3.4.1. General Methods 
The bridging bonds linking each monomeric unit in the tetrameric (30a and 31a) and 
dimeric (32a - 34a) complexes were cleaved with triphenylphosphine using one of 
two methods. Reaction of 32a - 34a with triphenylphosphine was carried out despite 
the solids being a crude mixture as it was believed that if the chloro-bridged dimer 
was indeed present, it would be the only complex in the mixture to be cleaved with 
triphenylphosphine, hence only one product would be isolated. 
The complexes 30a and 31a were suspended in dry, deoxygenated acetone and 
triphenylphosphine was added. The resulting mixture was stirred at room 
temperature for 4 hours; the products (30b and 31b) were filtered and washed with 
cold acetone (Scheme 3.3.). 
Scheme 3.3. 
30a: R = CH2CH3 
31a: R= CH3 
PPh3/ Acetone • 
30band 31b 
Complexes 32a - 34a were suspended in dry, deoxygenated OCM and 
triphenylphosphine added (Scheme 3.4.). The reaction mixture was stirred for 24 
hours at room temperature, filtered and the crude product was precipitated by 
addition of hexane. Recrystallisation of the crude products from a mixture of OCM 
and hexane gave the pure complexes 32b - 34b. 
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32a: R = 3,4-<llchloro; R' = H 
33a: R = 3,5-bis(trlfluoromethyl); R' = CH3 
348: R = 3,5-b1s(trlfluoromethyl); R' = H 
Scheme 3.4. 
3.4.2. Physical Properties 
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32b -33b 
Complexes 30b - 34b were isolated as yellow or orange solids. Table 3.9. 
summarizes the yields and melting points for these complexes. 
Table 3.9.: Physical Appearance. Yields and Melting points for 30b - 34b 
Complex Yield (%) Physical Appearance Melting Point 
30b 72 Yellow Solid 280-283°C 
3ib 75 Yellow Solid decamp. 290-291 °C 
32b 49 Orange solid 249-251°C 
33b 63 Orange solid 207-209°C 
34b 59 Orange solid 135-136°C 
In contrast to their dimeric starting complexes (32a - 34a), complexes 32b - 34b 
exhibit good solubility in most organic solvents. Complexes 30b and 31 b show the 
same limited solubility as their tetrameric analogues 30a and 31a. 
3.4.3. Spectroscopic and Analytical Characterization 
Complexes 30b - 34b are new complexes and were fully characterized using NMR 
and IR spectroscopies, mass spectrometry and elemental analysiS. NMR 
experiments were recorded in DMSO-d6 for 30b and 31 band CDCb for 32a - 34b~ 
I R spectra were recorded as KBr pellets. 
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Nuclear Magnetic Resonance (NMR) Spectroscopy 
Complexes 30b - 34b (Figure 3.6.) were characterized using proton, carbon, 
phosphorus and, in the case of 33b and 34b, fluorine NMR spectroscopy. Table 
3.10. summarizes the 1H, 31PCH} and 19FCH} NMR data and the 13C NMR shifts are 
listed in Table 3.11. 
For cyclopalladated complexes 30b and 31b, the amino (-Ntb) protons are observed 
in the proton NMR as a singlet at 6.88 and 6.79 ppm respectively, similar to 
previously synthesized cyclopalladated thiosemicarbazone phosphine complexes.2o 
For the coordination complexes 32b - 34b, these protons are assigned to peaks 
observed further upfield between 4.77 - 5.01 ppm, in agreement with analogous 
[N,S] chelate Pd(lI) thiosemicarbazone complexes.21 
R' 
~~f ~/NyNH2 d I ~ N ~ R- \ c I #a Pd __ s 
b CI-- \ 
PPha 
30band 31b 32b· 34b 
Figure 3.6. Structures of monomeric complexes 30b - 34b 
The protons for triphenylphosphine are observed In the expected region as broad 
multiplets. The peak for the imine proton of complex 32b is observed as a doublet at 
7.87 ppm with a coupling constant of 8.56 Hz, corresponding to long range proton to 
phosphorus coupling, as well as coordination of the triphenylphosphine co-ligand 
trans to the imine nitrogen.22 Splitting of the imine proton for complex 34b could not 
be ascertained as its peak overlaps with that of two aromatic protons of the 
thiosemicarbazone ligand. 
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Table 3.10.: 1 H. 31 pC Hl and 19F{1 Hl NMR data for complexes 30b - 34b 
31p 1H 19F 
Complex R R' (ppm) H-C=N N.I:b Aromatic Other C& (ppm) (ppm) Protons (ppm) (ppm) (ppm) 
7.40-7.74 (m, 2.82 (C.!::i2), 30b 3,4-dichloro Et 38.55 - 6.88 PPh3), 7.21 (s, 1.11 -Hb), 6.34 (s, He) (CH~) 
7.42-7.64 (m, 2.76 3ib 3,4-dichloro Me 38.75 - 6.79 PPh3), 7.20 (s, (CH3) -Hb), 6.10 (s, He) 
8.47 (m, Hb, He), 
32b 3,4-dichloro H 27.10 7.87 4.93 7.70-7.80 (m, PPh3), 7.40-7.55 -- -
(m, PPh3, Ha) 
8.19 (s, 2H, Ha, 
3,5- He), 7.93 (s, 1 H, 
33b bis(trifluoro- Me 29.22 4.77 Hc), 7.46-7.63 (m, 2.52 -62.93 - 6H, PPh3), 7.36- (CH3) methyl) 7.45 (m, 9H, 
PPh3) 
8.66 (s, 2H, Ha, 
3,5- He), 7.89 (s, 1 H, 
34b bis(trifluoro- H 27.74 8.69 5.01 Hc), 7.74-7.80 (m, - -63.38 
methyl) 6H, PPh3), 7.45-7.54 (m, 9H, 
PPh3) 
s = singlet, d = doublet, dd = doublet of doublets and m = multiplet 
The 31PCH} NMR spectrum show  a singlet at ca. 38.50 ppm for complexes 30b and 
31b and a singlet between 27.00 and 29.20 ppm for complexes 32b - 34b. These 
resonances agree with those of similar complexes and further support coordination 
of phosphorus trans to the imine nitrogen. 2, 18,22 
Cleavage of the Pd-Sbridging bonds in 30a and 31a by triphenylphosphine to yield 
complexes 30b and 31 b results in a downfield shift for the signal due to the thiol 
carbon to approximately 176.0 ppm. The alkyl carbons of the R' group occur slightly 
upfield compared to the tetrameric analogues (30a and 31a). 
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Table 3.11.: 13CCH} NMR Data for Complexes 30b - 34b 
Complex ~=N(ppm) ~·s (ppm) ~.rom.uc) (ppm) Other (ppm) 
164.1 (Ca). 151.5 (Ct). 136.5 (Cd). 19.5 «(QH2). 10.9 30b 168.2 176.9 133.9 - 128.6 (Ccand PPh3). 126.3 
JCe). 125.9 (Cb) (QH3) 
152.7 (Ca). 136.1 (Ct). 133.8 (Cd). 
3ib 163.6 176.6 1 ~3. 7 (Cc). 128.5-:131.1 (PPh3). 13.0 (CH3) 
126.2 (Ce). 126.1 (Cb) 
32b 150.9 175.8 128.3-134.6 (Ca. Cb• Cc• Cd. Ce• Ct 
-and PPh3) 
33b 165.7 172.1 142.3 (Cd. 128.0·134.1 (Ca. Cb• Cc• 123.1 (CF3). 21.8 Cd. Ce and PPh3) (CH3) 
34b 149.6 177.0 128.4·134.6 (Ca. Cb• Cc• Cd. Ce• Ct 123.7 (CF3) and PPh3) 
In 30b the imine carbon resonates at a similar shift to 30a and is slightly more 
shielded in complex 31b compared to 31a. For complexes 32b - 34b, the thiol 
carbon is observed between 172.0 - 177.0 ppm. The imine carbon for 32b and 34b, 
where the R' substituent is a hydrogen, resonate at a similar shift which is upfield 
from that observed for 33b, where the R' substituent is a methyl group which may 
result in deshielding of the imine carbon. For all of the complexes, the aromatic 
carbons of the thiosemicarbazone and the triphenylphosphine ligands are observed 
in the expected region, between 126.0 and 165.0 ppm. 
Infrared (lR) Spectroscopy 
Selected infrared absorption bands for 30b - 34b are listed below in Table 3.12. 
Table 3.12: Selected IR Absorption Bands for 30b - 34b 
Complex N·H (em-) C=N (em-1 ) 
30b 3466,3289 1618, 1577 
3ib 3474.3332 1601, 1579 
32b 3468.3365 1595. 1581 
33b 3446 1624,1603 
34b 3461.3341 1607. 1577 
Absorption bands similar to that of their multimeric analogues (30a - 34a, Table 3.8.) 
are observed for the C=N and N-H vibrations in 30b - 34b. As with complexes 30a -
34a, the low frequency band observed for the imine vibrations is aSSigned to the 
C=N bond coordinated to palladium. For complex 33b, a broad absorption band, 
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possibly due to overlapping of the N-H vibrations is observed for the two N-H bonds 
at 3446 cm-1• 
Mass Spectrometry and Elemental Analysis 
The tetrameric complexes 30a and 31a as well as complexes 30b - 34b were further 
characterized using ESI-mass spectrometry and elemental analysis. Table 3.13. lists 
the fragments corresponding to the proposed molecular formulae for these 
compounds. 
Table 3.13. Mass Spectral Results for Complexes 30a - 34b 
Complex Calculated Molar Mass (glmol) Molecular Fragment Assignment 
30a 1522.36 1522 [Mt 
31a 1466.24 1468 [M + 2Hf+ 
30b 642.88 644 [M + Ht 
31b 628.85 630 [M+Ht 
32b 651.28 615.95 [M -C~+ 
33b 732.42 695.98 [M-Clt 
34b 718.98 681.99 [M-Cq+ 
The C, H, Nand S values found for these compounds are within acceptable limits 
compared to their calculated values. 
3.5. X-ray Crystallography 
Single crystals were grown by slow evaporation of OMSO from the NMR sample for 
complex 30b and from a OCM-hexane mixture for complex 32b. Their molecular 
structures were elucidated using single crystal X-ray diffraction and validate the 
spectroscopic and analytical characterization of the cyclopalladated (30b and 31 b) 
and the bis-chelated (32b - 34b) thiosemicarbazone palladium(II) complexes. The 
molecular structure of 30b is shown in Figure 3.7. and 32b in Figure 3.8. Table 3.14. 
lists the crystallographic data for both molecular structures. Selected bond lengths 
and angles are given in Table 3.15. 
Complex 30b crystallizes with an orthorhombic system and space group Pca21. In 
the crystal system, the terminal amine of one complex molecule intermolecularly 
hydrogen bonds to the oxygen of two solvent molecules. 
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Figure 3.7.: Molecular structure of 30b with ellipsoidal model of probability 
level = 40%. The hydrogen bonds are shown as dotted lines 
Table 3 14 : CrvstalloqraDhic Data for complexes 30b and 32b 
''" "" Empiricallormula C"" H""CI"N,o"PPdS, C,.H" CI,.N,PPdS 
Empirical We~ht 799.09 651,24 
Crystal sin O.15xO.14 x O.11 mm O.12xO.11 xO.09mm 
Crysta l system, space g roup Orttlorhombic, Pca2, Moooclinic, P2/c 
• 15.6030{6) A 17.01 41(5! A 
" 
9,61 ;?g(2) A 20.0919(6) 
, 23.0082(4) A 17.4680(4) A 
alpha 0000, 00<>0, 
bela 00'00 116.139(2)deg, 
gamma 90deg 90 deg 
Volume 3451,00(16) A' , 5265,6(3) A' 
, , , 
... 
Calcu lated dens ity 1.538 Mgfm' , 1.643 Mgim' 
F(OOO) 1632 
""" R indices (all data) Rl E 0,0417, wR2. 00077 Rl· 0,0883, wR2 = 0.1153 
The Ihiosemicarbazone ligand bonds to the paliadium(lI) atom in the expected 
[C,N,S] fashion forming two five-membered chelate rings?3 The fourth coordination 
site on the metal is occupied by a triphenylphosphine ligand Inspection of the ang les 
formed between the metal and the coordinated atoms show that the metal is 
contained within a slightly distorted square-planar environment The angles N(3)-
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Pd(1)-S(1) 82.48(8) and N(3)-Pd(1)-C(4) 81.30(12) formed between the 
thiosemicarbazone ligand and the metal are less than 90°. The angles P( 1 )-Pd( 1 )-
S(1) 99.85(3) and P(1)-Pd(1)-C(4) 96.55(10) are therefore greater than 90°. 
Collectively the bite angles observed in the molecular structure compare favourably 
with those of analogous cyclopalladated triphenylphosphine complexes.2,3 
The bond lengths between palladium and the donor atoms are within the range of 
2.03 and 2.33 A with the shorter bond distances occurring between the metal and 
the N(3) and C(4) atoms. The strong trans influence of the phosphorus atom is 
reflected in the Pd(1 )-N(3) bond distance which is slightly longer than the expected 
length calculated from the covalent radii of palladium and nitrogen (2.01 A).2,3,23A 
C( 1 )-S( 1) bond length of 1. 762( 4) is consistent with single bond character and 
confirms that sulfur bonds to the metal in the thiolate form, additionally the C(1 )-N(2) 
bond length substantiates the formation of a double bond upon deprotonation of the 
hydrazinic nitrogen.2,3 
Table 3.14.: Selected Bond Lengths and Angles for Complexes 30b and 32b 
Complex30b Complex32b 
Pd(1)-S(1) 2.3324(9) A 2.2403(14) A 
Pd(1)-P(1) 2.2614(9) A 2.2487(14) A 
Pd(i)-N(3) 2.036(3) A 2.111(4)A 
Pd(1)-CC4) 2.038(4) A -
PdCi)-CI(1) - 2.3447(14) A 
CCi)-SC1) 1.762(4) A 1.746(6) A 
C(1)-NC2) 1.324(5) A 1.319(7) A 
C(2)-NC3) 1.299(4) A 1.289(7) A 
N(3)-Pd(1 )-S(1) 82.48(8) 0 83.37(12) 0 
N(3)-Pd(i )-C(4) 81.30(12) 0 
-
N(3)-Pd(i)-CI(1) 
-
95.90(12) 0 
P(1 )-Pd(1 )-8(1) 99.85(3) 0 92.11(5) 0 
P(i)-Pd(1)-C(4) 96.55(10) 0 
--
P(1)-Pd(1)-CI(i) 
-
88.63(5) 0 
Figure 3.8. shows the molecular structure of complex 32b. The complex crystallizes 
with a monoclinic P21/C system. There are two complex molecules per asymmetric 
unit. 
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Fi ~ lIfe 3.8. Molecular structure of 32b showing the asym metric unit with atomic latlell i ng sctleme 
Ellipsoidal model ~ were draw al40% probabH y level. All hydrogen atoms are omitted for clarity. 
The lhiosemicarbazone ligand (32) coordinates to palladium via the imine nitrogen 
and thiolato sulfur forming a five membered chelate ring. The other two coordination 
sites on palladium are occupied by a chlorido ligand and triphenylphoshine; the 
triphenylphosphine ligand is coordinated trans to the imine nitrogen. Inspection of the 
bond angles formed between the donor atoms and palladium correspond to a slightly 
distorted square-planar environment around the metal. 
The Pd(1)-S(1) (2,2403(14) A), Pd(1)-P(1) (2.2487(14) A), Pd(1)-N(3) (2.111(4) A) 
and Pd(1)-CI(1) (2.3447(14) A) bond distances are analogous to complexes of this 
type reported ill the litera ture: i ,24 The value observed for the C(1 )-S(1) bond 
distance (1 746(6) A) is closer to the bond length expected for a C-S single bond 
(1.82 A) than that of a normal C=S double bond (1.56 A),2~ corroborating that sulfur 
coordinates to palladium in the thiolato form. 2e The C(1 )-N(2) and C(2)-N(3) bond 
distances of the complex are similar indicating increased double bond character for 
the C(1 )-N(2) bond supporting formation of a new imine bond in the 
thiosemicarbazone ligand upon coordination of sulfur to palladium,27-zg 
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The bite angles P(1)-Pd(1)-5(1) and P(1)-Pd(1)-CI(1) (92.11(5t and 88.63(5t 
respectively) show the least deviation from 900 , thus the greastest deviation is 
observed for the N(3)-Pd(1 )-5(1) and N(3)-Pd(1 )-CI(1) bite angles that of 83.37(12) 0 
and 95.90(12) 0 respectively. Overall, the bond angles observed are comparable to 
literature examples of these types of bidentate thiosemicarbazone Pd(lI) 
complexes.21 ,24 
3.6. Conclusion 
The complexation of thiosemicarbazone ligands 30 - 34 have shown that the 
position of the substituents on the aryl-ring and the size of the substituent present on 
the imine carbon influence the bonding mode of aryl-thiosemicarbazones to 
palladium. 
Ligands 30 and 31, where the imine substituent is an alkyl group (Me, Et), form 
tridentate cyclopalladated tetrameric complexes (30a and 31a) when reacted with 
K2[PdCI4] while bidentate chloro-bridged dimers (32a) is isolated for the 3,4-dichloro-
benzaldehyde thiosemicarbazone derivative (32). 
For thiosemicarbazones 33 and 34, reaction with the palladate salt yields a mixture 
of products (possibly isomers) as observed in the proton NMR, and the position and 
size of the aryl substituents may hinder C-H activation of the ligands. 
Cleavage of the Pd-5brldging (30a and 31a) and the Pd-Clbrldglng (32a - 34a) bonds was 
achieved by reaction of the corresponding tetra mer or dimer with triphenylphosphine 
yielding monomeric complexes (30b - 34b).The molecular structures of 30b and 32b 
were determined using X-ray diffraction and confirm the solid state structures of all of 
the mononuclear complexes synthesized. 
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Chapter 4: Biological and Catalytic Activity of Thiosemicarbazone Ligands 
and their Paliadium(1Il Complexes 
4.1. Biological Studies 
The metal chelating abilities of thiosemicarbazones are believed to partially account 
for their biological activity. These compounds contain several donor atoms that could 
chelate to a metal within the cell giving rise to the actual active species. In addition, 
several other factors have contributed to the steady rise in biological research of 
their metal complexes. The bioactivities of thiosemicarbazones may be beneficially 
altered upon coordination to a metal.1 The lipophilic nature of the complex might be 
enhanced compared to the free ligand and certain long term side effects may 
decrease or may be altogether avoided since metal complexes can break down and 
the metal ion can then interact with the organism.2-4 In addition, the metal complex 
could exhibit bioactivities not shown by the free thiosemicarbazone ligand and 
coordination could yield a significant reduction in drug resistance.1 
As discussed in Chapter 1 (Section 1.2.1.), the high toxicity of cisplatin led to the 
investigation of other platinum complexes which exhibit the same beneficial 
properties but are less toxic. Carboplatin ([ diamine( cyclobutane-1 ,1-
carboxylato)platinum(II)]), one of the second generation platinum(lI) drugs 
discovered, has shown activities equivalent to cisplatin but with a markedly lower 
toxicity.5,6 As part of this search for improved antitumoral drugs relative to cisplatin, 
paliadium(lI) complexes were also amongst the first to be used in clinical trials since 
they exhibit similar aqueous chemistry to those of platinum(II).7 However, 
paliadium(lI) complexes are generally thermodynamically and kinetically less stable 
than Pt(II) complexes and this accounted for the lower activity and higher toxicity of 
complexes cis-Pd(NH3)CI2 and Pd(1,2-diaminocyclohexane)2CI2 compared to their 
platinum analogues.7-9 
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Since these first discoveries, the preparation of Pd(lI) complexes with inert ligands 
such as sulfur donors grew in importance after it was suggested that N,S chelates of 
Pd(lI) are better antitumor agents than those of other metals. The N,S chelate 
complexes of other metals do not have sufficient thermodynamic stability while 
platinum(lI) N,S chelates are kinetically inert. In contrast, palladium(ll) chelates 
possess the proper lability to transport the metal to DNA, allowing it to interact with 
't 10 I. 
In this regard, thiosemicarbazones have arisen as an excellent class of N,S donor 
ligands in the search for better antitumoral paliadium(lI) complexes. 
Thiosemicarbazones display anticancer activity and it is believed that their 
mechanism of action is through the inhibition of ribonucleotide reductase. 11 Their use 
in conjunction with Pd(II), which is known to damage DNA, produces a synergistic 
effect which could potentially lead to the development of more effective cancer 
chemotherapies. Thus, the study of Pd(lI) thiosemicarbazone complexes as 
anti proliferative agents has emerged as an area of great importance. 
Pd(lI) complexes of aryl derived thiosemicarbazones have been tested for 
antitumoral and anticancer activity against several cancer cell lines including, 
human and murine tumor resistant cell lines that are resistant and sensitive to 
cisplatin,12-14 human breast cancer 15 and bladder cancer.15 In certain cases, the 
Pd(lI) complexes were found to be better cytotoxic agents than cisplatin as well as 
their free ligands. A tridentate phenanthrenequinone thiosemicarbazone Pd(ll) 
complex was found to exhibit superior selectivity toward breast cancer tumor cells 
which have previously shown resistance to conventional chemotherapies.16 
The antiplasmodial activity of thiosemicarbazones against Plasmodium fa/ciparum 
strains has been reported.17-22 These compounds are believed to affect processes 
associated with haemoglobin (Hb) digestion in the food vacuole of the paraSite 
through several possible inhibitory mechanisms of action. The thiosemicarbazone 
could act as a metal chelator that coordinates via its donor atoms to endogenous 
metals such as Fe(lll), which is critical for the biological activity of a number of 
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plasmodial proteins, thus inhibiting the growth of the malaria parasite by withholding 
it from metal dependent enzymes such as cysteine and aspartic proteases.20.22 
Secondly, they could co-bind metals and substrate recognition sites consequently 
enhancing the natural inhibitory effects of endogenous metals on protease catalytic 
sites.23 
Thirdly, thiosemicarbazones are believed to inhibit cysteine proteases within the 
malaria parasite through covalent modification of the cysteine thiol groups either via 
the electophilic centers (thione carbon and/or imine carbon) of the 
thiosemicarbazone moiety. The main function of Plasmodium cysteine proteases is 
haemoglobin (Hb) hydrolysis which, provides amino acids for parasite protein 
synthesis,24.25 provides space for the growing parasite 26 and sustains the osmotic 
stability of malaria parasites.27 Thus modification of the cysteine thiol within the 
active site needed for hydrolysis inhibits the enzyme. 
The use of thiosemicarbazone metal complexes as antimalarial agents is sparse. 
Copper(II), nickel(lI) and iron(lI) complexes of 2-acetyl pyridine derived 
thiosemicarbazones have been screened for antimalarial activity.28 The Cu(lI) and 
Fe(lI) complexes were found to exhibit modest activity compared to their free ligands 
while the Ni(lI) complexes showed no activity. The investigation of 
thiosemicarbazone Pd(l/) complexes as antimalarial agents has not been reported in 
the literature. 
A preliminary biological study of selected thiosemicarbazones prepared (26 - 31) 
and their corresponding paliadium(lI) complexes (26a - 29a, 30b and 31b) was 
undertaken. These compounds were tested in vitro for activity against several cancer 
cell lines and two strains of P. falciparum. In addition, apoptosis experiments were 
carried out for ligand 27. 
4.1.1. Anticancer Activity 
The salicylaldehyde derived thiosemicarbazones ligands (26 - 29) and their 
corresponding Pd(lI) complexes of type (salicylaldiminato 
thiosemicarbazone)Pd(PPh3) (26a - 29a) were evaluated in vitro for activity as 
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anticancer agents. All of the compounds were first screened for activity against the 
cancer cell line WHC01, an oesophageal cancer cell line of South African origin with 
Doxorubicin as the control drug (Table 4.1.). 
The compounds showing the best activity were then screened against several other 
cell lines. Figure 4.1. shows the structures of the ligands and paliadium(lI) 
complexes tested. Activities for these compounds are expressed as IC5o, the 
compound concentration required for 50 % inhibition in vitro. The ligand, 3)butyl-2-
hydroxy benzaldehydethiosemicarbazone (27), showed the best activity (IC5o = 1.10 
~M) out of all compounds screened against the WHC01 cell line. However, its 
corresponding complex (27a) exhibited moderate to weak cytoxicity (IC5o = 54.38 
~M). 
26: R = 5-Chloro 
27: R = 3-tert. Butyl 
28: R = 3-Methoxy 
29: R= H 
EX:~N""N~NH2 R-:- I I '" O-Pd--S I 
PPh3 
268: R = 5-Chloro 
278: R = 3-tButyl 
288: R = 3-Methoxy 
298: R= H 
Figure 4.1. Structures of thiosemicarbazones and their corresponding palladium(lI) complexes tested 
for anticancer activity 
Similarly, ligand 26 shows better activity than its corresponding complex (26a). The 
opposite effect is observed for compound 28, its complex (28a) impressively showed 
a value almost 40 times lower than its IC50 value of 95.13 ~M. In the case of complex 
28a, this difference in activity may be due to one of two factors; coordination of the 
thiosemicarbazone to palladium may alter its lipophilic character thus increasing 
activity or it may be a synergistic effect, the ligand dissociates within the cell and 
interacts with the ribonucleotide reductase enzyme while the free metal ion interacts 
with DNA.15.29 
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Table 4.1. IC§Q8 Values for Compounds 26 - 29a Against the WHC01 Cell Line 
Compound IC50 [JIM] 95% Confidence. Interval 
26 10.83 9.31 -12.59 
27 1.10 0.91 -1.28 
28 95.13 71.61-126.40 
29 b - -
26a 24.00 19.27 - 29.90 
27a 54.38 15.70 -188.3 
28a 2.56 2.33 -2.82 
29a 6.68 6.35-7.03 
Doxorubucln 0.58 0.48-0.70 
• 
... 
." ICoo. compound concentration causing 50 % inhibition In Vitro, --. inactive at the highest 
concentration tested 
Interestingly, ligand 29 was not active at the maximum concentration used while its 
palladium complex (29a) showed good activity; coordination of thiosemicarbazone 
29 to palladium clearly modifies its cytotoxic properties most likely by increasing its 
lipophilic nature. Out of all the Pd(II) complexes tested, complex 28a shows the 
greatest cytotoxic activity with an IC50 value of 2.56 !-1M. 
Inspection of the results obtained for the free ligands (26 - 29) shows that having a 
substituent on the aryl ring increases the activity of the compound however; the 
degree of activation may be dependent on the position of the substituent as well as 
the inductive effect of the substituent. Compound 28 has a strongly electron donating 
substituent in position 3 on the ring yet it does not show any appreciable activity 
while thiosemicarbazone 27, where the tertiary butyl group donates electron density 
into the ring to a lesser extent than 28, shows the best activity. Compound 26 has an 
electron-withdrawing chloro-substituent on the ring and it exhibits intermediate 
activity; better than 28. This may be explained by the fact that the chloro group is in 
position 5 on the ring. It is possible that the position as well as the electronic nature 
of the aromatic substitutent may influence the way the ligand binds within the 
enzyme pocket. Further studies regarding the structure-activity relationship of these 
compounds need to be undertaken in order to establish the actual consequence of 
the aromatic substituent. These observations however, cannot be extended to their 
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corresponding complexes which do not show a trend regarding the substituents on 
the ring. 
In a previous study, cisplatin has shown an IC50 value of approximately 13 IJM 
against the WHC01 celiline.3o The free ligands 26 and 27 as well as complexes 28a 
and 29a all exhibit cytotoxicities lower than this value against this cell line. An actual 
comparison to cisplatin is not possible as these compounds are neither structurally 
similar to cisplatin nor were they screened with cisplatin in the same experiment. 
Nevertheless, it would be interesting to investigate the activity of these compounds 
(26, 27, 28aand 29a) in vitro together with clinically used drugs in order to ascertain 
if they are more potent inhibitors. 
The three compounds showing the best activities, ligand 27 and palladium 
complexes 28a and 29a, were then screened against two additional oesophageal 
cancer cell lines of South African Origin (WHC05 and WHC06), five oesophageal 
cancer cell lines of Japanese Origin (KYSE30, KYSE70, KYSE180, KYSE410 and 
KYSE450) and two cervical cancer cell lines (CaSki and HeLa). The results are 
shown in Table 4.2. along with their activity against WHC01. 
Table 4.2. IC&a Values for Compounds 27. 28a and 29a Against Several Cancer 
Cell Lines 
Ligand 27 Complex28a Complex29a 
95% 95% 95% 
Cell Line IC50 [IJMJ Confidence IC50 [IJMJ Confidence IC50 [IJMJ Confidence 
Interval Interval Interval 
WHC01 1.10 0.91 -1.28 2.56 2.33 -2.82 6.68 6.35-7.03 
WHC05 4.03 3.47-4.69 2.11 0.69-6.39 n/d nld 
WHC06 6.32 5.05-7.92 12.23 5.40-27.70 43.13 15.00-124.00 
KYSE30 3.02 2.21-4.13 1.48 1.11-1.96 3.76 2.63-5.39 
KYSE70 7.98 6.66-9.56 b 10.28 8.14-12.97 
- -
KYSE180 7.27 6.46-8.19 5.23 - 6.43 5.40-7.65 
KYSE41 0 7.46 6.48-8.59 46.02 23.51-90.11 - -
KYSE450 1.64 1.33-2.02 2.19 1.42-3.36 4.11 2.86-5.91 
CaSkl 13.03 9.56-17.75 - - - -
HeLa 0.91 0.79-1.06 
- --
70.61 61.81-80.67 
B o • . .. 
." .' IC50• compound concentration causing 50 Yo Inhibition In Vitro, -. inactive at the highest 
concentration tested 
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The free thiosemicarbazone ligand 27, showed good activity against all of the cell 
lines screened with the best activity observed in the cervical cancer cell line HeLa. 
Complex 28a exhibited good IC50 values against cell lines WHC01, WHC05, 
KYSE30, KYSE180 and KYSE450; intermediate activity against WHC06 and 
negligible activity against KYSE410 cell lines. It did not show any activity against the 
remaining cell lines at the highest concentrations used (200 IJM). Complex 29a 
displayed good activity in only four of the oesophageal cancer cell lines tested; was 
not active in the CaSki line and showed negligible activity against the HeLa cell line. 
Complex 29a and similar rO,N,S] tridentate thiosemicarbazone Pd(lI) analogues 
have been previously screened for in vitro anticancer activity against the 
promyelocytic HL-60 and histiocytic lymphoma U-937 cell Iines.31 Most of these 
complexes exhibited IC50 values less than 10 IJM. In addition, they were found to be 
more potent cytotoxic agents than the human clinical drugs cisplatin, BCNU (1,3-
bis(2-chloroethyl)-I-nitrosourea), hydroxyurea and 5-FU (5-fluorouracil) which were 
also screened during the same experiments.31 Similarly, complex 29a has displayed 
activities lower than 10 IJM in four of the oesophageal cell lines tested. 
In the WHC05 cancer cell line, complex 28a shows better activity (IC5o = 2.11 IJM) 
than compound 27 (IC5o = 4.03 IJM) and this is also observed for the KYSE30 and 
KYSE180 cell lines. Complex 29a demonstrated an IC50 value comparable to ligand 
27 (IC5o = 3.02 IJM) but was almost 2.5 times less active than 28a against KYSE30. 
Both complexes are more active than 27 against KYSE180 while neither complex 
exhibits activity against the CaSki line. Overall, thiosemicarbazone 27 was found to 
be a good cytotoxic agent, it consistently displayed good activity against all cell lines 
tested while the complexes 28a and 29a only exhibited cytotoxicity against selected 
cell lines. 
Due to the favourable IC50 values observed for ligand 27 against almost all cell lines 
treated, dose-response curves were determined for ligand 27 and its corresponding 
Pd(lI) complex 27a in the HeLa and WHC01 cell lines, the two cancer cell lines 
where ligand 27 displayed its lowest IC50 values (0.91 and 1.10 IJM respectively). 
Complex 27a displayed poor cytotoxicity during the initial screening of the 
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compounds 26 - 29a against WHC01, therefore its dose-response curves were 
determined merely for comparison purposes. In addition, apoptosis experiments for 
these cell lines were carried out using ligand 27. Figure 4.2. shows the dose-
response curves ascertained for 27 and 27a against the HeLa and WHC01 cell 
lines. 
WHC01 tx Ligand 27 WHC01 tx Complex 27a 
1. 
E ~ 1. A Z * . . ~ I o. II) 
8 o. Q A 0 
11 11 o. 1 o. 1 
... ... 
... ... 8 o. 0 u 
o. 
'" 
·2 0 2 4 
'" 
·2 0 2 4 
Log [Drug) J1M Log [Drug) J1M 
HeLa tx Ligand 27 HeLa tx Complex 27a 
o. , 
itiA E E 
• • iI* Ji o. c 
en = 
A 
II) II) O. 
Q O. Q 
0 0 i 0 11 o. ~ ... 
~ 0 ... 
u 8 0.1 
O. 
'" 
·2 0 2 4 
'" 
·2 0 2 4 
Log [Drug) J1M Log [Drug) J1M 
Figure 4.2. Dose-response curves for 27 and 27a against the HeLa (below) and WHC01 (above) cell 
lines. 
WHC01 cells treated with ligand 27 gave an IC50 of 5.52 JJM (4.72-6.46 JJM 
confidence interval) and complex 27a was inactive against WHC01 cells as 
treatment at the highest concentration did not kill cells. HeLa cells were more 
sensitive to 27 than WHC01 cells with an IC50 of 0.64 JJM (0.60-0.70 JJM confidence 
interval). An IC50 value could not be obtained for the treatment of HeLa cells with 27a 
as the compound did not affect the proliferation of the cells. It is evident that ligand 
27 is very active against He La cells and that it does affect cell proliferation in 
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WHC01 celis. The metal complex 27a was completely inactive against both Hela 
and WHC01 cell lines, this could be a result of poor solubility of the compound. 
PARP (Poly Adenosine-Diphosphate Ribose Polymemse) cleavage was investigated 
by Western bioi analysis in order to detennine the mode of cell death induced by 
ligand 27. Figure 4.3. shows the western blot diagrams for this experiment. 
A B 
c".r 
c . .. " ""' 
'_T"'," 
Legend: 
A: HeLa cells treated with 27 
B: WHC01 cells treated with 21 
Unix: untreated cells: negauye contr~ 
Dox: doxorub);;oin-treated cells: postitive control 
,.'" 
c.""',,,' ",' 
O_T"",~ 
Figure 4.3. Western Blot diagrams for HeLa and WHC01 cells treated with ligand 27 
PARP is a known caspase substrate and cleavage of PARP into two distinct 
fragments (116kDa and 85kDa) serves as a marker of apoptosis, Apoptosis is the 
process of programmed cell death which involves a series of biochemical steps 
resulting in morphological changes to the cell membrane including cell shrinkage, 
nuclear fragmentation and chromosomal DNA fragmentation,~" Hela cells treated 
with three concentrations of thiosemicarbazone 27 showed considerable cleavage of 
PARP whereas WHC01 cells treated with this oompound showed no PARP 
cleavage, Treatment of cells with 5IJM doxorubicin served as a positive control. 
From these results it is evident that 27 kills Hela cells via apoptosis, The mode of 
cell death for WHC01 cells at the above treatment concentrations of 27 is clearly not 
apoptosis and it might be interesting to investigate whether 27 triggers cell death in 
WHCQ1 cells by necrosis (premature death of cells usually induced by disruption of 
cell membrane) 33, senescence (loss of cell's ability to divide due to DNA double 
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strand breaks or toxins) or autophagy (degradation of a cell by separating the 
contents from the rest of the cytoplasm).34 
4.1.2. Antimalarial Activity 
The compounds tested for anticancer activity, thiosemicarbazones 26 - 29 and Pd(lI) 
complexes 26a - 29a, as well as ligands 30 and 31 (Figure 4.4.) and their 
cyclopalladated complexes (30b and 31 b) were evaluated for antimalarial activity in 
vitro against the P. fa/ciparum strains, W2 (chloroquine resistant) and 010 
(chloroquine sensitive) and the data are listed in Table 4.3. The control drugs used 
in the experiment were chloroquine (CO) and artemisinin (ART) for the W2 strain 
and chloroquine for the 010 strain. 
CI 
CI 
R 
308: R = CH2CH3 
318: R= CH3 
CI 
CI 
R 
~i/NINH2 
--Pd--S 
I 
PPho 
30b: R = CH2CH3 
31b: R= CH3 
Figure 4.4. Structures of thiosemicarbazones 30 and 31 and their corresponding complexes, 30b and 
31b 
For the 010 strain, the compounds were first screened for percentage parasite 
survival at a single concentration in order to determine the most active compounds 
for which, IC50 values were ascertained. All of the ligands (26 - 31) as well as 
complex 31 b showed cell survival close to or greater than 50 %. The lowest 
percentage cell survival was observed for complex 29a (27 %) with complexes 26a, 
28a and 30b displaying percentage survivals between 31 and 38 %. 
From the ICoo values obtained for these complexes against the 010 strain, 
complexes 268' and 30b exhibit good activity; complexes 28a and 29a also show 
good activity. It is interesting to note that the two complexes showing the best 
activities against this strain have chloro (26a) and dichloro (30b) substituents on the 
Un
ive
rsi
ty 
of 
 C
ap
e T
ow
n
90 
aryl ring. Complex 29a, the unsubstituted paliadium(lI) salicylaldimine 
thiosemicarbazone, is less active than complex 28a, where the aryl substituent is 
the electron-donating methoxy group. 
Table 4.3.: In vitro Activity Against P. falciparum strains W2 (chloroquine resistant) 
and 010 (chloroquine sensitive) 
Compounds 010 Percentage Survival (10 IIg/ml) 010 IC50 (11M) W2IC50 (11M) 
26 107.21% nld >20 
27 102.59% nld >20 
28 48.62% nld >20 
29 56.18% nld >20 
30 53.57% n/d >20 
31 48.75% nld >20 
268 37.67% 1.38 >20 
27a 51.68% nld 13.74 ± 2.19 
28a 33.47% 5.64 10.75 ± 0.44 
29a 26.88% 9.02 8.87 ± 2.00 
30b 31.01% 0.37 >20 
31b 46.37% nld >20 
CQ n/d 0.0598 0.097 ± 0.00092 
ART n/d n/d 0.019 ± 0.0023 
nld = not determined 
Relative to their free ligands (27 - 29), the metal complexes 27a - 29a showed 
superior antiplasmodial activity against the W2 strain. Whereas the ligands 
showed no activity at the highest concentration tested (20 ~M), the corresponding 
metal complexes (27a - 29a) showed activities in the range of 8 - 13 ~M. Ligands 
30 and 31 and their corresponding complexes (30b and 31 b) showed activities 
greater than ICso = 20 ~M. 
Overall, complex 29a showed similar activities against W2 and 010, while none of 
the free ligands showed appreciable activity against either strain. It is evident that 
chelation of the ligand to palladium enhances antimalarial activity. This may be 
through increasing the lipophilic character of the overall complex, and thus 
favouring permeation through the cell membrane. The differences in 
antiplasmodial activities observed for the complexes suggest that, 1) the aromatic 
ring of the coordinated thiosemicarbazone ligand may be involved in the 
mechanism of inhibition and 2) the effect of the aryl substituent is not electronic 
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but may be attributed to steric effects. Further studies of the complexes found 
active as well as their free ligands need to be undertaken in order to ascertain the 
actual inhibitory effects of these compounds. Additionally, screening of these 
compounds aQainst mammalian cells is required in order 
4.2. Catalytic Studies 
The Suzuki-Miyaura cross coupling reaction is considered to be one of the most 
efficient methods for the construction of carbon-carbon bonds.35 It involves reaction 
of an organo-boronic acid with an aryl or alkenyl halide and was first reported by 
Miyaura and Suzuki in 1979,36,37 with the 'classic' reaction of phenyl boronic acids 
and aryl halides being reported in 1981.38 
Pd(lI) complex 
1~ "-., ....... 10. 
Ar-Br 
Pd(O) Species \"'01"'" ",Hlo. 
I-Ph Pdll-Br J 
III 
OH 
I Base-B--Base Na-8ase 
I Na+ 111- Base OH 
OH Ai 
/OH I II Ph-\ Na-8ase .. Ph-j-ease 
OH OH 
Figure 4.5. Basic catalytic cycle of the Suzuki-Miyaura coupling reaction 
Figure 4.5. depicts the generally accepted catalytic cycle of this reaction.35,39 The 
paliadium(lI) complex is reduced in situ to the active Pd(O) species, usually by use of 
Un
ive
rsi
ty 
of 
 C
ap
e T
ow
n
92 
a base, to a zerovalent species which can undergo oxidative addition of the aryl 
halide to intermediate I. Reaction with a base followed by transmetalation of a 
nucleophilic carbon from boron to the intermediate (II) gives III which undergoes 
rapid reductive elimination of the cross-coupled product and the regeneration of the 
Pd(O) catalyst.39 
The application of palladium(II) thiosemicarbazone complexes as catalyst precursors 
for cross-coupling reactions is little known. One of the earliest reports was only 
published in 2004 describing their use in the Heck coupling reaction.4o Three 
salicylaldehyde derived thiosemicarbazone palladium(II) complexes (Figure 4.6.) 
have been applied to the Suzuki-Miyuara coupling reaction and were shown to 
catalyze carbon-carbon bond formation in the presence ofwater.41 ,42 
25 8a 
Figure 4.6.: Structures of Pd(lI) complexes previously used for the Suzuki-Miyaura cross-coupling 
reaction 
To test the versatility of the tridentate thiosemicarbazone Pd(II) complexes prepared, 
complexes 26a - 29a, 30b and 31 b were evaluated for preliminary activity as 
catalyst precursors for the Suzuki-Miyaura coupling reaction (Scheme 4.1.).41 A 0.1 
mol % of each complex was applied to the coupling of either bromobenzene or 4-
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bromo-anisole with phenylboronic acid at 100 °C over 24 hours in a Dr-..,1F-water 
mixture, using N<l:!CO, <lS b<lse Bromob€nzene is <l st<lnd<lrd substr<lte used in 
catalytic studies of <lryl-<lryl coupling and 4-bromoanisole was chosen since the 
electron-don ... ting methoxy substituent strengthens the C-Br bond, making oxidative 
insertion of palladium into the bond difficult. 
G.' "0" .'; m " ,"" ' 
'_ F " -" •• ,, ,' [f,' . ...... " , 
H" ''.0' "" 
SCleme 4.'" 
The products of the reactions were detected using gelS chromeltogrelphy (GC) with 
dec ... ne ... s internell st ... ndmd, Figure 4.7, shows the percent convers'lon of aryl halide 
substrelte elnd Figure 4,8 shows the TON (turnover number) of each catalyst 
calculelted from GC, 
30 
7,. 
W 
i 
'" 
:;; 
• ., i 
" 
0 
• 
" 
" 
0 
'"" "" '"" 
,," 
'" '" 
. "", conv ...-sion {b,om OLt-!1Zt-!1e i ie '% conyers; on i ~-IHOInoani s o ,,:' 
F'QurG 4.7. % Gomers ions for CO'l1p exes 26~ 29a, 3Ob, 31 b 
In all of the reelctions. the deposition of palladium black was not obsell/ed, 'Indicating 
that the catalysts <lre st<lble in air as well ... s in tile presence of welter, elt 100"C All 
of the complexes sllowed higher percent conversions for the 4-bromo-anisole 
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substrate_ For complexes 26a - 29a, the percent convorsions obseNed for the 4-
bromo-anisole substrate '.'lere similar to each other, ranging between 71 and 75 %. 
This is surprising since substrates containing an electron-donating group arc known 
to genorally show lower conversions to coupled products. Complex 268 exhibited a 
conversion of 52 % for tho bromobcnzcno substrato while complex 298 showed the 
highest conversion to product for this substrate 
Complexos JOb and 31b wore loss active than complexes 2603 - 290'1 Similar percent 
conversions were displayed by 30b for both aryl bromido substrates and complex 
31b ShOlNS the 101'0'851 conversion of bromo-benzene out of all tho comploxes. 
Overall complex 29a was the most effective catalyst showing good conversions for 
either substrate, 
"00 
;00 
CC" 
~,oo 
z 
0 
"" ~ 
.1 ()(J 
!(J[) 
j(J[) 
" 
'" 
>1b 
FigLlm 4.8. TOrj {:ur'lOw,.- nLl '''h~rj for c<;..-npl~,"" 26~ 29~, 30b, 31 b 
With regard to actual actiVe palladium specieS in these reactions, it is unlikely that a 
Pd{O) specios is the activo catalyst. All of the comploxes used are Pd(ll) complexes 
and dissociation of triphenylphosphine which is a neutral donor leaves Pd in the +2 
state While the generally accepted catalytic cycle for the Suzuki-Miyaura cross 
coupling reaction is bolieved to be a Pd(O)/Pd(ll) system (Figure 4,5 ),';:;'"" there is 
another pathway that has been postulated using a Pd(ll) complex as active 
catalyst.'''·,1" The bas'lC catalytic cycle possibly utilized by complexes 26a - 29a. 30b 
and 31b involving a Pd(II)/Pd(lI) catalytic pathway is outlined in Figure 4.8:15 
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(I) 
X-Pd"-S 
I 
PPh3 
x=c,O 
rN~ ( ) = tridentate 
x S thiosemicarbazone ligand 
Ph-Ph 
Transmetallation 
Ph-Br 
(I) 
x.... Pd"-S 
I 
Ph 
Figure 4.8. Possible catalytic cycle using complexes 26a - 29a, 30b and 31 b based on observations 
discussed in reference 45. 
Upon dissociation of triphenylphosphine, rapid transmetallation probably takes place 
by pre-coordination of the phenyl boronic acid followed by fast metathesis with the 
aryl bromide to give the coupled product.45•46 This is only a proposed mechanistic 
pathway, further studies would need to be carried out in order to ascertain the actual 
active species. For instance, in order to confidently rule out catalysis by colloidal 
Pd(O) or molecular Pd(O), the mercury test could be employed. This would determine 
if the carbon-carbon bond formation is actually catalyzed by a homogenous 
palladium complex that is in a higher oxidation state.45 Computational studies as well 
as NMR studies of the intermediates could also prove effective. 
4.3. Conclusion 
The preliminary biological evaluation of compounds 26 - 31, 26a - 29a, 30b and 31 b 
have shown that thiosemicarbazone 27 is an effective cytotoxic agent exhibiting 
activity against all the cell lines screened. Complexes 28a and 29a have also 
displayed good activity in selected cell lines. PARP cleavage experiments have 
shown that 27 may induce cell death by apoptosis in the WHC01, while its mode of 
inhibition in HeLa cells is uncertain. 
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Complexes 26a and 30b showed superior antiplasmodial activity against the 
chloroquine sensitive (010) P. fa/ciparum strain. All of the paliadium(lI) complexes 
generally exhibited better activity than their corresponding free ligands against either 
parasite strain. 
The presence of a substituent on the aryl ring of the thiosemicarbazone ligand may 
influence biological activity, however further studies need to be undertaken with 
regard to structure-activity relationships to ascertain the actual effect. 
Complexes 26a - 29a, 30b and 31b have been shown to successfully catalyze 
carbon-carbon bond formation between phenyl boronic acid and two aryl bromide 
substrates. Moderate to good percent conversions were obtained with the 
complexes exhibiting selectivity towards the 4-bromo-anisole substrate. The results 
obtained are promising and warrant further investigation into the catalytiC activity of 
these complexes as carbon-carbon cross-coupling catalyst or catalyst precursors. 
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Chapter 5: Experimental 
5.1. General Experimental Procedures 
All complexation reactions were performed under a nitrogen or argon atmosphere 
using a dual vacuum/nitrogen line and standard Schlenk-line techniques. All reaction 
solvents were dried by refluxing under an inert atmosphere over the appropriate 
drying agent and all samples were dried under vacuum. Thiosemicarbazide, 
5-chloro-2-hydroxy-benzaldehyde, 3-tert-butyl-2-hydroxybenzaldehyde, 2-hydroxy-3-
methoxy-benzaldehyde, 2-hydroxy-benzaldehyde, 3,4-dichloro-benzaldehyde, 3,4-
dichloro-acetophenone, 3,4-dichloro-propiophenone, 3,5-bis(trifluoromethyl)-
benzaldehyde and 3,5-bis(trifluoromethyl)-acetophenone were purchased from 
Aldrich and used without further purification. Paliadium(lI) chloride was kindly 
donated by Johnson-Matthey Inc. Potassium tetrachloropalladate,1 dichloro(1,5-
cyclooctadiene)paliadium(lI) 2 and dichloro-bis(triphenylphosphine)paliadium(lI) 3 
were prepared according to literature methods. 
Nuclear Magnetic Resonance (NMR) spectra were recorded on a Varian Unity 
XR400 MHz (1H at 399.95 MHz, 13C at 100.58 MHz, 31p at 161.90 MHz, 19F at 376.9 
MHz) or Varian Mercury XR300 (1H at 300.08 MHz, 13C at 75.46 MHz, 31p at 121.47 
MHz) MHz spectrometer at ambient temperature. Chemical shifts for 1H, 19F{1H} and 
13C{1H} NMR shifts are reported using tetramethylsilane (TMS) as the internal 
standard and 31 p{1 H} spectra were measured relative to H3P04 as the external 
standard. 
Infrared absorptions (IR) were measured on a Perkin-Elmer Spectrum One FT-IR 
Spectrometer as KBr pellets. Microanalyses for C, H, Nand S were carried out using 
a Thermo Flash 1112 Series CHNS-O Analyser and melting points were determined 
using a Kofler hot stage microscope (Reichert Thermovar). Mass Spectrometry 
determinations were carried out on all new compounds using electron spray 
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ionisation on a Waters API Quattro Micro instrument in the positive or negative 
mode. 
5.2. Preparation of Thiosemicarbazone Ligands 
5.2.1. General Preparation of Thiosemicarbazones 
A solution of the appropriate aldehyde or ketone in ethanol (10 cm3) was added 
dropwise to a stirred suspension of thiosemicarbazide in ethanol (20 cm3). Acetic 
acid (1cm3) was added to the reactions where a ketone is used. The reaction 
solution was refluxed, either for 6 hours in the case of the aldehyde 
thiosemicarbazones or 18-20 hours for the ketone thiosemicarbazones. Upon 
cooling to room temperature, the product precipitated out of solution and is collected 
by filtration, washed with ethanol and diethyl ether and dried under vacuum. 
5.2.1.1. 5-Chloro-2-hydroxybenzaldehyde thiosemicarbazone (26) 4 
e g H h j 
CI 
::::".. N/NyNH, 
S 
b 
Thiosemicarbazide (0.168 g, 1.850 mmol) was reacted with 5-chloro-2-
hydroxybenzaldehyde (0.203 g, 1.300 mmol). The product (26) was isolated as a 
crystalline white solid (0.131 g, 44%). M.p.: 292-295 °C (lit. m.p.: 290 °C). 1H NMR 
(300.08 MHz, DMSO): ~ (ppm) = 11.33 (br s, 1 H, HI), 10.08 (br s, 1 H, Hk) 8.32 (s, 
1H, Hg), 8.01 (brs, 3H, He, Hj), 7.20 (d, 3J(HbHe) = 8.73 Hz, 1H, Hb), 6.87 (d, 3J(HeHb) 
= 8.73 Hz, 1H, He). 13C NMR (75.46 MHz, DMSO): ~ (ppm) = 178.0 (Ci), 155.0 (Ca), 
137.6 (Cg), 130.2 (Ce), 125.4(Ce), 123.3 (Cd), 122.2 (Cb), 117.6 (Ct). IR (KBr, cm-1) u 
= 3406 (m, O-H), 3235 (m, N-H), 3166 (s, N-H), 3044 (w, N-H), 1612 (m, C=N), 1542 
(s, C=C aromatics), 1099 (m, C=S). 
.'. 
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5.2. 1.2. 3-tert.-Butyl-2-hydroxybenzaldehyde thiosemicarbazone (27) 
e 
h 
g HI n 
:::::""N/N'rNH' 
S 
27 
Thiosemicarbazide (0.271 g, 2.977 mmol) was reacted with 3-tert.-butyl-2-
hydroxybenzaldehyde (0.520 g, 2.920 mmol). The product (27) was isolated as a 
white solid (0.397 g, 54%). M.p.: 254-257 °C. 1H NMR (300.08 MHz, DMSO): (5 
(ppm) = 11.29 (s, 1H, HI), 10.03 (br s, 1H, Ho), 8.28 (s, 1H, Hg), 7.99 (br s, 2H, Hn), 
7.25(m, 2H, He, He), 6.86 (t, 3J(HeHdHe) = 7.69 Hz, 1H, Hd), 1.40 (s, 9H, Hh, Hi. HJ). 
13C NMR (75.46 MHz, DMSO): (5 (ppm) = 1.77.8 (Cm), 155.3 (Ca), 147.0 (Cg), 136.6 
(Cb), 129.3 (Ce), 128.2 (Ce), 119.1 (Ct), 118.4 (Cd), 34.3 (Ck), 29.2 (Ch, Cj, CJ) . IR 
(KBr, cm-1) U = 3419 (s, O-H), 3248 (s, N-H), 3164 (s, N-H), 3038 (s, N-H), 1614 (s, 
C=N), 1537 (s, C=C aromatics), 1148 (m, C=S). Elemental Analysis for C12H17N30S: 
found C 56.92 H 6.73 N 16.71 S 12.63 %; calculated C 57.34 H 6.81 N 16.72 S 
12.76 %. ESI-MS: mlz 252.11 [M + Ht. 
5.2.1.3. 2-Hydroxy-3-methoxybenzaldehyde thiosemicarbazone (28) 5 
e g H h j,k 
:::::""N/NyNH, 
S 
0 ............. I 
28 
Thiosemicarbazide (0.352 g, 3.847 mmol) was reacted with 2-hydroxy-3-
methoxybenzaldehyde (0.585 g, 3.847 mmol). The product (28) was isolated as a 
white solid (0.814 g, 94%). M.p.: 216-217 °C (lit. mp.: 220-222 °C). 1H NMR (400 
399.95 MHz, DMSO): (5 (ppm) = 11.34 (s, 1 H, Hh), 9.12 (br s, 1 H, Hm), 8.39 (s, 1 H, 
Hg), 8.04 (s, 1 H, Hj), 7.82(s, 1 H, Hk), 7.50 (d, J = 7.80 Hz, 1 H, He), 6.94 (dd, 4J(HeHe) 
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= 1.34, 3 J(HeHd) = 7.98 Hz, 1 H, He), 6.75 (t, 3 J(HeHdHe) = 7.97 Hz, 1 H, Hd), 3.79 (s, 
3H, HI). 13C NMR (75.46 MHz, DMSO): l) (ppm) = 177.8 (Ci), 147.8 (Ca), 145.9 (Cb), 
139.8 (Cg), 120.6 (Ce), 118.9 (Ce), 118.2 (Cd), 112.9 (Ct), 55.8 (CI). IR (KBr, cm-1) u = 
3461 (s, O-H), 3344 (s, N-H), 3167 (s, N-H), 3033 (m, N-H), 1598 (s, C=N), 1538 (s, 
C=C aromatics), 1060 (m, C=S). 
5.2.1.4. 2-Hydroxybenzaldehyde thiosemicarbazone (29) 6 
g H h j,k 
~N/NyNH2 
S 
e 
b 
Thiosemicarbazide (0.396 g, 4.346 mmol) was reacted with 2-hydroxybenzaldehyde 
(0.504 g, 4.129 mmol). The product (29) was isolated as a pale yellow solid (0.610 g, 
76%). M.p.: 292-295°C (lit. m.p.: 210°C). 1H NMR (399.95 MHz, DMSO): l) (ppm) = 
11.31 (s, 1H, Hh), 9.83 (br s, 1H, HI), 8.35 (s, 1H, Hg), 8.04 (s, 1H, Hj), 7.85-7.88 (m, 
2H, He, Hk), 7.17-7.19 (m, 1H, He), 6.78-6.86 (m, 2H, Hb, Hd). 13C NMR (75.46 MHz, 
DMSO): l) (ppm) = 177.8 (Ci), 156.3 (Ca), 140.0 (Cg), 130.9 (Ce), 126.8 (Ce), 120.1 
(Cd), 119.1 (Cb), 116.0 (Ct). IR (KBr, cm-1) u =3444 (m, O-H), 3319 (s, N-H), 3173 (s, 
N-H), 3029 (m,br, N-H), 1614 (s, C=N), 1538 (s, C=C aromatics), 1111 (m, C=S). 
5.2.1.5. 3,4-Dichloropropiophenone thiosemicarbazone (30) 7 
30 
CI 
Thiosemicarbazide (0.227 g, 2.491 mmol) was reacted with 3,4-
dichloropropiophenone (0.500 g, 2.464 mmol). The product (30) was isolated as a 
fluffy white solid (0.184 mmol, 27%). M.p.: 188-190 °c (lit. mp.: 185.6-186.4 °C). 1H 
NMR (399.95 MHz, DMSO): l) (ppm) = 10.36 (s, 1 H, Hj), 8.31 (s, 1 H, HI)' 8.23 (s, 1 H, 
Ha), 8.13 (s, 1H, Hm), 7.86 (dd, 4J(HeHa) = 2.80, 3J(HeHd) = 8.55 Hz, 1H, He), 7.61 (d, 
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3J(HdHe) = 8.54 Hz, 1H, Hd), 2.86 (q, J = 7.55,7.55 Hz, 2H, Hh), 0.98 (t, J = 9.41 Hz, 
3H, Hi). 13C NMR (75.46 MHz, DMSO): ~ (ppm) = 179.2 (Ck), 149.3 (Cg), 136.9 ((4), 
131.5 (Cc), 131.4 (Cb), 130.2 (Ca), 128.2 (Cd), 126.7 (Ce), 18.9 (Ch), 10.5 (C,). IR 
(KBr, cm-1) u = 3389 (m, N-H), 3254 (m, N-H), 3174 (m, N-H), 1595 (m, C=N), 1512 
(s, C=C aromatics), 1054 (s, C=S). 
5.2.1.6. 3,4-Dichloroacetophenone thiosemicarbazone (31) 7 
CI 
CI 
31 
Thiosemicarbazide (0.546 9, 5.987 mmol) was reacted with 3,4-
dichloroacetophenone (1.002 9, 5.303 mmol). The product (31) was isolated as a 
fluffy white solid (0.485 9, 35%). M.p.: 191-192 °c (lit. mp.: 196 - 198°C). 1H NMR 
(300.08 MHz, DMSO): ~ (ppm) = 10.20 (br s, 1 H, HI)' 8.26 (s, 1 H, Ha), 8.13 (br s, 2H, 
Hk), 7.90 (d, 3 J(HdHe) = 8.52 Hz, 1 H, Hd), 7.66 (d, 3 J(HeHd) = 8.52 Hz, 1 H, He), 2.33 
(s, 3H, Hh). 13C NMR (75.46 MHz, DMSO): ~ (ppm) = 179.1 (Cj), 145.2 (Cg), 138.2 
((4),131.5 (Cc), 131.2 (Cb), 130.0 (Cd), 128.0 (Ca), 126.5 (Ce), 13.6 (Ch). IR (KBr, cm-
1)u=3421 (s, N-H),3181 (m, N-H), 3141 (m, N-H), 1594(s, C=N), 1091 (s, C=S). 
5.2.1.7. 3,4-Dichloro-benzaldehyde thiosemicarbazone (32) 7 
e g Hh 
"""N/NIlNH' j 
S 
c' 
32 
CI 
Thiosemicarbazide (0.131 9, 1.436 mmol) was reacted with 3,4-
dichlorobenzaldehyde (0.225 9, 1.287 mmol). The product (32) was isolated as a 
fluffy white solid (0.135 9, 42%). M.p.: 195-198°C (lit. mp.: 202-204°C8). 1H NMR 
(399.95 MHz, DMSO): ~ (ppm) = 11.51 (s, 1H, Hh) 8.21 (br s, 3H, Hg, Hj), 7.98 (s, 
1H, Ha), 7.71 (d, 3J(HdHe) = 8.37 Hz, 1H, Hd), 7.63 (d, 3J(HeHd) = 8.33 Hz, 1H, He). 
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13C NMR (75.46 MHz, DMSO): ~ (ppm) = 178.3 (CI), 139.4 (Cg), 134.9 (Ce), 131.7 
(Cb), 131.6 (Ct), 130.5 (Cd), 128.0 (Ca), 127.4 (Ce). IR (KBr, cm-1) u = 3397 (m, N-H), 
3256 (m, N-H), 3156 (s, N-H), 1597 (s, C=N), 1540 (s, C=C aromatics), 1103 (m, 
C=S). 
5.2.1.8. 3,5-Bis(trifluoromethy/)acetophenone thiosemicarbazone (33) 7 
h 
33 
Thiosemicarbazide (0.074 g, 0.8185 mmol) was reacted with 3,5-
bis(trifluoromethyl)acetophenone (0.213 g, 0.833 mmol). The product (33) was 
isolated as a fluffy white solid (0.111 g, 41%). M.p.: decomposition without melting 
240-241 °c (lit. m.p.: decomposition without melting 238°C). 1H NMR (399.95 MHz, 
DMSO): ~ (ppm) = 10.33 (s, 1 H, Hi), 8.52 (s, 2H, Ha. He), 8.33 (s, 2H, Hk), 8.05 (s, 
1 H, He), 2.34 (s,3H, Hh). 13C NMR (100.58 MHz, DMSO): ~ (ppm) = 180.1 (Cj), 145.9 
(Cg), 141.2 (Ct), 131.3 (Cb, Cd), 127.9 (Ca, Ce), 125.4 (Ce), 122.7 (Cit Cm), 14.9 (Ch). 
19F NMR (376.9 MHz, CDCI3): ~ = -61.59 (CF3). IR (KBr, cm-1) u = 3436 (m, N-H), 
3257 (s, N-H), 3163 (s, N-H), 1602 (s, C=N), 1507 (m, C=C aromatics), 1118 (m, 
C=S). 
5.2.1.9. 3,5-Bis(trifluoromethy/)benza/dehyde thiosemicarbazone (34) 7 
Thiosemicarbazide (0.189 g, 2.077 mmol) was reacted with 3,5-bis(trifluoromethyl) 
benzaldehyde (0.500 g, 2.065 mmol). The product (34) was isolated as a fluffy white 
solid (0.176 g, 27%). M.p.: 225-227 °c (lit. m.p.: 229.8-230.3 °C). 1H NMR (399.95 
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MHz, OMSO): ~ (ppm) = 11.68 (s, 1 H, Hh), 8.52 (s, 2H, Ha, He), 8.43 (s, 1 H, Hj), 8.34 
(s, 1H, Hj), 8.16 (s,1H, Hg), 8.03 (s, 1H, He). 13C NMR (100.58 MHz, OMSO): ~ (ppm) 
= 179.4 (CI), 139.7 (Cg), 138.0 (Ct), 132.0 (Cb, Cd), 128.5 (Ca, Ce), 125.4 (Ce), 123.0 
(Ck, CI). 19F NMR (376.9 MHz, COCh): ~ = -61.74 (CF3). IR (KBr, cm-1) u = 3451 (s, 
N-H), 3303 (s, N-H), 3174 (s, N-H), 1601 (s, C=N), 1535 (s, C=C aromatics), 1152 
(s, C=S). 
5.3. Preparation of Palladium Complexes 
5.3.1. General Preparation of [Pd(Salicylaldiminato thiosemicarbazone)(PPh3)] 
Complexes 
The appropriate thiosemicarbazone ligand (1 mol equiv.) was added to dry ethanol 
(40 cm3) and the solution heated to 60°C with stirring. Triethylamine (2.1 mol equiv.) 
was added followed by Pd(PPh3)2CI2 (1 mol equiv, complexes 26a - 29a) or Pd(4-
pic)2Cl2 (1 mol equiv, complexes 26b - 29b) and the resulting mixture was refluxed 
for five hours unless otherwise stated. Upon cooling to room temperature, the 
precipitated product was isolated via filtration, washed with ethanol (10 cm3) and 
diethyl ether (10 cm3). Complexes 26a-29a were purified by recrystallization from a 
mixture of OCM and hexane and complexes 26b - 29b were recrystallized from 
chloroform. 
5.3.1.1. [Pd(5-Ch/oro-2-hydroxybenza/dehyde thiosemicarbazone)(PPh3)] (26a) 
e g ij 
./NiNH2 ~N,r "=::: 
I O-Pd--S 
I 
PPh3 
268 
Oichlorobis(triphenylphosphine)paliadium(lI) (0.513 g, 0.731 mmol) was reacted with 
5-chloro-2-hydroxybenzaldehyde thiosemicarbazone (0.162 g, 0.706 mmol). The 
reaction was refluxed for 2 hours and the crude product precipitated out of solution. 
Recrystallization from OCM-Hexane yielded the product (26a) as a crystalline yellow 
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solid (0.262 g, 63% yield). M.p.: 221-223 °C. 1H NMR (300.08 MHz, COCI3): ()(ppm) 
= 8.13 (d, 4JpH = 13.62 Hz, 1H, Hg), 7.66-7.75 (m, 6H, PPh3), 7.26-7.55 (m, 9H, 
PPh3), 7.23 (d, 4J(HeHc) = 2.75, 1H, He), 7.11 (d, 3J(HcHb) = 9.02 Hz, 1H, Hc), 6.59 
(d,3J(HbHc) = 9.02 Hz, 1H, Hb), 4.74 (s, 2H, Hi, Hj). 13C NMR (75.46 MHz, COCh): () 
(ppm) = 171.5 (Cg), 161.2 (Ch), 149.6 (Ca), 128.3-134.7 (PPh3, Cc, Cd and Ce), 122.2 
(Ct), 118.7 (Cb). 31p NMR (121.47 MHz, COCI3): () (ppm) = 25.23 (PPh3). IR (KBr, 
cm-1) u = 3493 (N-H), 3385 (m, N-H), 3054 (w, C-N), 1605 (s, C=N), 1586 (m, C=N), 
.1529 (s, C=C aromatics). Elemental Analysis for C26H21CIN30PPdS: found C 51.96 
H 3.55 N 5.83 S 4.76 %; calculated C 52.36 H 3.55 N 7.05 S 5.38 %. ESI-MS: rnIz 
597 [M + Hr, 100%. 
5.3.1.2. [Pd(3-tert.-Buty/-2-hydroxybenza/dehyde thiosemicarbazone)(PPh3)] (27a) 
g m,n 
-"':::::::N" ~ ./NjNH2 
I 
O-Pd--S 
I 
PPh3 
278 
Oichlorobis(triphenylphosphine)paliadium(lI) (0.530g, 0.755 mmol) was reacted with 
3-tert.-butyl-2-hydroxybenzaldehyde thiosemicarbazone (0.215 g, 0.837 mmol). The 
reaction solution was refluxed for 4 hours and the crude product precipitated out of 
solution. Recrystallization from OCM-Hexane yields the product (27a) as a crystalline 
orange solid (0.136 g, 29%). M.p.: 234-236°C. 1H NMR (399.95 MHz, COCI3): () 
(ppm) = 8.26 (d, 4JpH = 14.14 Hz, 1H, Hg), 7.70-7.77 (m, 6H, PPh3), 7.38-7.48 (m, 
9H, PPh3), 7.20-7.37 (m, 2H, Hc, He), 6.57 (t, 3J(HcHdHe) = 8.82 Hz, 1H, Hd), 4.59 (s, 
2H, Hm, Hn), 0.744 (s, 9H, Hi, Hj, Hk). 13C NMR (100.58 MHz, COCI3): () (ppm) = 
170.0 (Cg), 162.2 (Ch), 152.3 (Ca), 140.3 (Cb), 128.0-135.1 (PPh3, Ce, Cc), 118.0 (Cd), 
114.1 (Ct), 34.79 (CI), 29.44 (CIJ,k). 31p NMR (161.90 MHz, COCI3): () (ppm) = 24.16 
(PPh3). IR (KBr, cm-1) u = 3464 (m, N-H), 3391 (m, N-H), 1634 (m, C=N), 1610 (s, 
C=N), 1593 (s, C=C aromatics). Elemental Analysis for C30H30N30PPdS: found C 
57.73 H 4.91 N 6.39 S 4.69 %; calculated C 58.30 H 4.89 N 6.80 S 5.19 %. ESI-
MS: rnIz 617 [M - Hr, 100%. 
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5.3.1.3. [Pd(2-Hydroxy-3-methoxybenzaldehyde thiosemicarbazone)(PPh3)] (28a) 
Oichlorobis(triphenylphosphine)palladium(ll) (0.516 g, 0.735 mmol) was reacted with 
2-hydroxy-3-methoxybenzaldehyde thiosemicarbazone (0.164 g, 0.728 mmol). The 
reaction was refluxed for 6 hours and the crude product precipitated out of solution. 
Recrystallization from OCM-Hexane yields the product (28a) as a dark orange 
crystalline solid (0.344 g, 80% yield). M.p.: 241-243 °c. 1H NMR (300.08 MHz, 
COCh): ~ (ppm)= 8.24 (d, 4JpH = 13.87 Hz, 1H, Hg), 7.49-7.81 (m, 6H, PPh3), 7.26-
7.49 (m, 9H, PPh3), 6.96 (d, 3J(HeHd) = 8.06 Hz, 1H, He), 6.85 (d, 3J(HcHd) = 7.57 
Hz, 1H, He), 6.56 (t, 3J(HeHdHe) = 7.79 Hz, 1H, Hd), 4.67 (s, 2H, Hi, Hj), 3.57 (s, 3H, 
Hk). 13C NMR (75.46 MHz, COCh): ~ (ppm) = 170.4 (Cg), 150.9 (Ch and Cb), 128.3-
134.8 (PPh3, Ca), 126.5 (Ce), 117.7 (Cd), 115.5 (C,), 113.9 (Ce), 56.6 (Ck). 31p NMR 
(121.47 MHz, COCh): ~ (ppm) = 19.67 (PPh3). IR (KBr, cm"1) u = 3442 (m, N-H), 
3308 (w, N-H), 1642 (m, C=N), 1592 (s, C=N), 1526 (s, C=C aromatics). Elemental 
Analysis for C27H24N302PPdS: found C 53.67 H 4.32 N 6.10 S 5.17 %; calculated 
C 54.78 H 4.09 N 7.10 S 5.42%. ESI-MS: mlz 591 [M - Ht, 100%. 
5.3.1.4. [Pd(2-hydroxybenzaldehyde thiosemicarbazone)(PPh3)] (29a) 9 
e g ij 
~rNiN~ 
O-Pd S 
I 
P~ 
29a 
Oichlorobis(triphenylphosphine)paliadium(lI) (0.514 g, 0.733 mmol) was reacted with 
2-hydroxybenzaldehyde thiosemicarbazone (0.146 g, 0.746 mmol). The reaction 
solvent was concentrated under reduced pressure and the crude product 
precipitated out of solution. Recrystallization from OCM-Hexane yielded the product 
(29a) as a crystalline orange solid (0.149 g, 36%). M.p.: 228-231°C (lit. mp.: 230-232 
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°c 10). 1H NMR (399.95 MHz, COCh): ~ (ppm) = 8.27 (d, 4JpH = 13.50 Hz, 1 H, Hg), 
7.70-7.75 (m, 6H, PPh3), 7.50-7.53 (m, 3H, PPh3), 7.43-7.48 (m, 7H, Hd and PPh3), 
7.28-7.43 (m, 3H, Hb, Hc, He), 4.69 (s, 2H, HI, Hj). 13C NMR (75.46 MHz, COCh): ~ 
(ppm) = 171.0 (Cg), 162.7 (Ch), 150.7 (Ca), 128.3-134.7 (PPh3, Ce, Cc), 120.7 (Cd), 
117.6 ('4), 114.8 (Cb). 31p NMR (121.47 MHz, COCI3) ): ~ (ppm) = 24.97 (PPh3). IR 
(KBr, cm-1) u = 3300 (w, N-H), 3132 (w, N-H), 1638 (m, C=N), 1599 (s, C=N), 1518 
(s, C=C aromatics). 
5.3.1.5. [Pd(5-Ch/oro-2-hydroxybenza/dehyde thiosemicarbazone)(4-pic)] (26b) 
m 
26b 
Oichlorobis(4-picoline)paliadium(lI) (0.394g, 1.089 mmol) was reacted with 5-chloro-
2-hydroxybenzaldehyde thiosemicarbazone (0.246 g, 1.070 mmol). The product 
(26b) precipitated out of solution as a yellow solid (0.137 g, 30 %). M.p.: 
decomposition without melting 238-240 °C. 1H NMR (300.08 MHz, COCh): ~ (ppm) = 
8.59 (d, 3J(HjHk) = 6.60 Hz, 2H, Hj), 7.83 (s, 1H, Hg), 7.16-7.44 (m, 3H, He, Hk), 6.94-
6.96 (m, 2H, Hb, Hc), 4.78 (s, 2H, Hi), 2.44 (s, 3H, Hm). 13C NMR (75.46 MHz, COCh): 
~ (ppm) 172.71 (Cg), 161.09 (Ch), 152.3 (Ca), 151.8 (Cj), 147.9 (CI), 132.7 (Cd), 132.3 
(Ce), 127.5 (Ck), 121.9 (Cc), 120.5 ('4), 117.9 (Cb), 21.29 (Cm). IR (KBr, cm-1) 1> = 
3403 (w, N-H), 3273 (w, N-H), 1622 (s, C=N), 1596 (s, C=N), 1518 (s, C=C 
aromatics). Elemental Analysis for C14H13N4CIOPdS: found C 40.76, H 3.40, N 
13.86, S 7.43 %; calculated C 39.36, H 3.07, N 13.11, S 7.51 %. ESI-MS: m/z 429 
([M + 2H]2+, 100%). 
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5.3.1.6. [Pd(3-tert.-Buty/-2-hydroxybenza/dehyde thiosemicarbazone)(4-pic)j (27b) 
Oichlorobis(4-picoline)paliadium(lI) (0.5019, 1.385 mmol) was reacted with 3-tert.-
butyl-2-hydroxybenzaldehyde thiosemicarbazone (0.349 9, 1.387 mmol). The 
reaction mixture was refluxed for 5 hours and the product (27b) precipitated out of 
solution as a fluffy yellow solid (0.285 9, 46%). M.p.: no meltin9 or decomposition up 
to 310 °C. 1H NMR (399.95 MHz, COCb): ~ (ppm) = 8.69 (d, 3J(HnHo) = 6.50 Hz, 2H, 
Hn), 7.97 (s, 1 H, Hg), 7.32-7.36 (m, 1 H, He), 7.18-7.25 (m, 3H, Hd, Ho), 6.79-6.42 (m, 
1H, He), 4.73 (s, 2H, Hi), 2.47 (s, 3H, Hq), 1.33 (s, 9H, Hk, HI, Hm). 13C NMR (75.46 
MHz, COCI3): ~ (ppm) = 169.8 (Cg), 161.8 (Ch), 152.0 (Ca), 151.7 (Cn), 150.8 (Cq), 
138.9 (Cb), 132.6 (Ce), 130.3 (Ce), 125.9 (Co), 118.7 (Cd), 114.3 (Ct), 35.2 (Cj), 29.4 
(Ck, CI, Cm), 21.2 (Cq). IR (KBr, cm-1) u = 3421 (m, N-H), 3310 (s, N-H), 1621 (br w, 
C=N), 1609 (s, C=N), 1591 (s, C=N), 1527 (s, C=C aromatics). Elemental Analysis 
for C1sH22N40PdS: found C 47.81, H 5.03, N 13.01, S 6.96 %; calculated C 48.16, H 
4.94, N 12.48, S 7.14 %. ESI-MS: rnIz 449 ([Mt, 100%). 
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5.3.1.7. [Pd(2-Hydroxy-3-methoxybenza/dehyde thiosemicarbazone)(4-pic)] (28b) 
Oichlorobis(4-picoline)paliadium(lI) (0.501 g, 1.385 mmol) was reacted with 2-
hydroxy-3-methoxybenzaldehyde thiosemicarbazone (0.312 g, 1.385 mmol). The 
reaction mixture was heated to 50°C for 2 hours. The reaction was then filtered and 
the volume of the filtrate reduced before being cooled, the product (28b) precipitated 
as a crystalline orange solid (0.155 g, 27 %). M.p.: 225-227 °C. 1H NMR (300.08 
MHz, COCI3): ~ (ppm) = 8.70 (d, 3J(HkHI) = 6.60 Hz, 2H, Hk), 7.97 (5, 1H, Hg), 7.14-
7.31 (m, 1 H, He), 6.95 -7.02 (m, 3H, Hd, HI), 6.52-6.68 (m, 1 H, He), 4.74 (5, 2H, Hi), 
3.85 (5, 3H, Hj), 2.43 (5, 3H, Hn). 13C NMR (75.46 MHz, COCh): ~ (ppm) = 170.5 
(Cg), 153.9 (Ch), 152.2 (Cb), 151.8 (Ck), 150.7 (Cm), 149.0 (Ca), 127.4 (CI), 126.2 
(Ce), 125.3 (Cd), 119.1 (Ct), 114.5 (Ce), 56.7 (Cj), 21.2 (Cn). IR (KBr, cm-1) u = 3428 
(br m, N-H), 3351 (br m, N-H), 1621(5, C=N), 1603 (5, C=N), 1525 (5, C=C 
aromatics). Elemental Analysis for C15H1sN402PdS %CHCh %CSH14: found C 
43.81, H 4.20, N 11.88, S 6.38 %; calculated C 43.54, H 4.65, N 11.88, S 6.34 %. 
ESI-MS: rnIz 423 ([Mt, 100%). 
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5.3.1.8. [Pd(2-Hydroxybenza/dehyde thiosemicarbazone)(4-pic)] (29b) 
Oichlorobis(4-picoline)paliadium(lI) (0.502 g, 1.382 mmol) was reacted with 2-
hydroxybenzaldehyde thiosemicarbazone (0.271 g, 1.387 mmol). Reaction solvent 
was concentrated under reduced pressure and the product (29b) precipitated out of 
solution as a crystalline orange solid (0.089 g, 34%). M.p.: decomposition without 
melting 185-187 °C. 1H NMR (399.95 MHz, COCI3): l5 (ppm) = 8.68 (d, 3J(HjHk) = 
6.57 Hz, 2H, Hj), 7.98 (s, 1H, Hg), 7.32-7.39 (m, 2H, He, He), 7.29 (d, 3J(HkHj) = 5.96 
Hz, 2H, Hk), 7.09 (d, 3J(HbHe) = 8.95, 1 H, Hb), 6.73 (t, 3J(HeHdHe) = 7.38, 1 H, Hd), 
4.85 (s, 2H, Hi), 2.49 (s, 3H, Hm). 13C NMR (75.46 MHz, COCh): l5 (ppm) = 170.0 
(Cg), 162.6 (Ch), 151.6 (Ca), 150.97 (Cj), 150.8 (CI), 133.9 (Ce), 133.6 (Ce), 126.3 
(Ck), 119.9 (Cd), 118.4 (Ct), 115.1 (Cb), 21.15 (Cm). IR (KBr, cm-1) u =3434 (w, N-H), 
3278 (w, N-H), 1625 (s, C=N), 1600 (s, C=N), 1588 (m, C=N), 1527 (s, C=C 
aromatics). 
5.3.2. General Preparation of Tetrameric Thiosemlcarbazone Palladium 
Complexes 
Potassium tetrachloropalladate (1 mol. equiv.) was dissolved in deionized water (5 
cm3). Ethanol (40 cm3) was added and the appropriate thiosemicarbazone ligand 
(1.1 mol. equiv.) was added to the resulting yellow suspension. The reaction mixture 
was stirred for 48 hours. The product was collected as a yellow solid via filtration, 
washed with ethanol (3 x 10 cm3) and dried under vacuum. 
Un
ive
rsi
ty 
of 
 C
ap
e T
ow
n
113 
5.3.2.1. [Pd(3,4-Dichloro-propiophenone thiosemicarbazone)]4 (30a) 
CI 
CI 
k 
~/Nlj NH2 g N 
I 
,,=---~--~ 
I I 
I I 
! : 
: i 4 
30a 
Potassium tetrachloropalladate (0.231g, 0.709 mmol) was reacted with 3,4-dichloro-
propiophenone thiosemicarbazone (0.201 g, 0.773 mmol). The product (30a) was 
isolated as a yellow solid by filtration (0.166 g, 61 %). M.p.: decomposition without 
melting 309-311 °C. 1H NMR (300.08 MHz, DMSO): l5 (ppm) = 7.36 (s, 1H, Hb), 7.11 
(s, 2H, Hk), 6.68 (s, 1H, He), 2.48 (dt, J = 1.88, 3.74 Hz, 2H, Hh), 0.925 (t, J = 7.52 
Hz, 3H, Hi). 13C NMR (100.58 MHz, DMSO): l5 (ppm) = 170.8 (Cj), 168.1 (Cg), 165.5 
(Ca), 149.4 (Ct), 134.2 (Cd, 130.3 (Cd), 126.9 (Ce), 126.3 (Cb), 21.1 (Ch), 12.0 (CI). IR 
(KBr, cm-1) l) = 3459 (m, N-H), 3376 (m, N-H), 1595 (s, C=N), 1561 (m, C=N), 1525 
(s, C=C aromatics). Elemental Analysis for C4oH36ClsN12Pd4S4: found C 31.36, H 
2.60, N 10.10, S 10.10 %; calculated C 31.56, H 2.38, N 11.04, S 8.43 %. ESI-MS: 
m/z 1522 ([C4oH36ClsN12Pd4S4t, 20%), 382 ([C10HgCI2N3PdSt, 100%). 
5.3.2.2. [Pd(3,4-Dichloro-acetophenone thiosemicarbazone)]4 (31a) 
CI 
. j 
~ /Nyl NH2 g N 
I 
;.I::---Pd--S 
I I 
I I 
I I 
! ; 
: i 4 
31a 
Potassium tetrachloropalladate (0.402 g, 1.230 mmol) was reacted with 3,4-dichloro-
acetophenone thiosemicarbazone (0.355 g, 1.356 mmol). The product (31a) 
precipitates out of solution as a yellow solid (0.326 g, 73 %). M.p.: decomposition 
without melting 307-309 °C. 1H NMR (399.95 MHz, DMSO): l5 (ppm) = 7.36 (s, 1H, 
Hb), 7.17 (s, 2H, Hj), 6.71 (s, 1 H, He), 1.99 (s, 3H, Hh). 13C NMR (75.46 MHz, 
DMSO): l5 (ppm) = 167.7 (Ci), 166.1 (Cg), 165.1 (Ca), 150.7 (Ct), 133.9 (Cc), 129.9 
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(Cd), 126.8 (Ce), 126.6 (Cb), 14.3 (Ch). IR (KBr, cm-1) u = 3442 (m, N-H), 3369 (m, N-
H), 1597 (s, C=N), 1560 (m, C=N), 1524 (s, C=C aromatics). Elemental Analysis for 
C36H2sClsN12Pd4S4: found C 29.14, H 2.43, N 10.87, 5 8.56 %; calculated C 29.44, 
H 1.93, N 11.46, 5 8.76 %. ESI-MS: mlz 1468 ([C36H2sClsN12Pd4S4 + 2Hr, 20%), 
368 ([CgH7CI2N3PdS + Hr, 100%). 
5.3.3. General Preparation of Dimeric Thiosemicarbazone Palladium 
Complexes 
The ligand (1 mol equiv.) was added to a stirred suspension of potassium 
tetrachloropalladate (1.1 mol equiv.) in dry ethanol (15 cm3) and the resulting 
reaction mixture was heated to 45°C for 24 hours. The reaction was then allowed to 
cool to room temperature and the product isolated via filtration, washed with cold 
ethanol (2 x 10 cm3) and dried under vacuum. 
5.3.3.1. [Pd(3,4-Dichloro-benzaldehyde thiosemicarbazone)Clh (32a) 
CI 
CI 
32a 
The ligand, 3,4-dichloro-benzaldehyde thiosemicarbazone (0.109 g, 0.440mmol) was 
reacted with potassium tetrachloropalladate (0.155 g, 0.475 mmol). The crude 
product (32a) was isolated as an orange solid (0.228 g, 45 % crude yield). M.p.: 
decomp. without melting 255-256°C. 1H NMR (300.08 MHz, DMSO): ~ (ppm) = 8.52 
(s, 1 H, Hg), 8.24 (s, 1 H, He), 7.91 (dd, 4J(HaHe) = 1.86, 3 J(HaHb) = 8.53 Hz, 1 H, Ha), 
7.63 (d, 3J(HbHa) = 8.50 Hz, 1H, Hb), 7.09 (s, 2H, HI)' 13C NMR (75.46 MHz, DMSO): 
~ (ppm) = 179.7 (Ch), 169.3 (Cg), 132.6 (Cc), 132.1 (Ce), 132.0 (Cb), 131.4 (Cd), 
130.1 (Ca), 130.7 (Ct). IR (KBr, cm-1) u = 3436 (br s, N-H), 1615 (s, C=N), 1560 (m, 
C=N), 1459 (m, C=C aromatics). 
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5.3.3.2. [Pd(3, 5-Bis(trifluoromethyl)acetophenone thiosemicarbazone )CI12 (33a) 
I 
F3C 
33a 
The ligand, 3,5-bis(trifluoromethyl)acetophenone thiosemicarbazone (1. 512 g, 
4.593 mmol) was reacted with potassium tetrachloropalladate (1.657 g, 5.076 mmol). 
The crude product (33a) was isolated as a fluffy orange solid (2.057 g, 95 % crude 
yield). M.p.: decomp. without melting 299-306 °C. 1H NMR (399.95 MHz, DMSO): a 
(ppm) = 8.53 (s, 2H, Ha, He), 8.19 (s, 1H, He), 7.19 (s, 2H, Hj), 1.81 (s, 3H, Hh). 19F 
NMR (376.9 MHz, DMSO): a (ppm) = -61.59 (CF3). IR (KBr, cm-1) U = 3409 (m, N-H), 
3308 (m, N-H), 1614 (s, C=N), 1579 (w, C=N). 
5.3.3.3. [Pd(3, 5-Bis(trifluoromethyl)benzaldehyde thiosemicarbazone )CI12 (34a) 
jCF3 
34a 
The ligand, 3,5-bis(trifluoromethyl)benzaldehyde thiosemicarbazone (0.448 g, 1.42 
mmol) was reacted with potassium tetrachloropalladate (0.507 g, 1.555 mmol). The 
crude product (34a) was isolated as a light orange solid (0.815 g, 63 %, crude yield). 
M.p.: decomp. without melting 270-276 °C. 1H NMR (399.95 MHz, DMSO): a (ppm) = 
8.71 (s, 2H, Ha , He), 8.45 (s, 1H, Hg), 8.12 (s, 1H, He), 7.31 (s, 2H, Hi). 19F NMR 
(376.9 MHz, DMSO): a (ppm). = -61.69 (CF3). IR (KBr, cm-1) U = 3469 (s, N-H), 3279 
(s, N-H), 1618 (s, C=N), 1582 (m, C=N). 
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5.3.4. Preparation of Monomeric Thiosemicarbazone Palladium Complexes 
5.3.4.1. Method A: Synthesis from Tetrameric Complexes 
The tetrameric complex (1 mol. equiv.) was suspended in dry acetone (15 cm3). 
Triphenylphosphine (4 mol. equiv.) was added and the reaction was stirred under 
argon gas for 4 hours. The product was collected as a bright yellow solid by filtration, 
washed with acetone (2 x 5 cm3) and dried under vacuum. 
5.3.4. 1. 1. [Pd(3,4-Dichloro-propiophenone thiosemicarbazone)(PPh3)] (30b) 
k 
~(NINH2 
CI -----r s 
b 
PPh3 
30b 
Triphenylphosphine (0.089 g, 0.338 mmol) was reacted with [{3,4-dichloro-
propiophenone thiosemicarbazone}Pd]4 (0.106 g, 0.0700 mmol). The product (30b) 
precipitated out of solution as a yellow solid (0.129 g, 72 %). M.p.: 280-283 °C. 1H 
NMR (300.08 MHz, DMSO): ~ (ppm) = 7.40-7.74 (m, 15H, PPh3), 7.21 (s, 1 H, Hb), 
6.88 (s, 2H, Hk), 6.34 (s, 1 H, He), 2.82 (q, J = 7.32, 7.29 Hz, 2H, Hh), 1.11 (t, J = 7.22 
Hz, 3H, Hi). 13C NMR (75.46 MHz, DMSO): ~ (ppm) = 176.9 (Cj), 168.2 (Cg), 164.1 
(Ca), 151.5 (Ct), 136.5 (Cd), 133.9 -128.6 (Ccand PPh3), 126.3 (Ce), 125.9 (Cb), 19.5 
(Ch), 10.9 (Ci). 31p NMR (121.47 MHz, DMSO): ~ (ppm) = 38.55 (PPh3). IR (KBr, 
cm-1) u = 3466 (m, N-H), 3289 (s, N-H), 1618 (s, C=N), 1577 (m, C=N), 1481 (s, C=C 
aromatics). Elemental Analysis for C2sH24CI2N3PPdS: found C 52.21, H 3.88, N 
5.93, S 4.55 %; calculated C 52.31, H 3.76, N 6.54, S 4.99 %. ESI-MS: rn/z 644 ([M 
+ Hr, 100%). 
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5.3.4.1.2. [Pd(3,4-Dichloro-acetophenone thiosemicarbazone)(PPh3)] (31b) 
CI 
CI 
b 
h 
. j 
~(NINH' 
;.1:----1 S 
PPh3 
31b 
Triphenylphosphine (0.073 g, 0.275 mmol) was reacted with [{3,4-dichloro-
aectophenone thiosemicarbazone}Pd]4 (0.100g, 0.069 mmol). The product (31 b) 
precipitated out of solution as a yellow solid (0.129 g, 75 %). M.p.: decomposition 
without melting 290-291 °C. 1H NMR (300.08 MHz, DMSO): 6 (ppm) = 7.42-7.64 (m, 
15H, PPh3), 7.20 (s, 1H, Hb), 6.79 (s, 2H, HJ), 6.10 (s,1H, He), 2.76 (s, 3H, Hh). 13C 
NMR (75.46 MHz, DMSO): 6 (ppm) = 176.6 (CI), 163.6 (Cg), 152.7 (Ca), 136.1 (Ct), 
133.8 (Cd), 133.7 (Cc), 128.5-131.1 (PPh3), 126.2 (Ce), 126.1 (Cb), 13.0 (Ch). 31p 
NMR (121.47 MHz, DMSO): 6 (ppm) = 38.75 (PPh3). IR (KBr, cm-1) U = 3474 (m, N-
H), 3332 (s, N-H), 1601 (s, C=N), 1579 (m, C=N), 1496 (s, C=C aromatics). 
Elemental Analysis for C27H22CI2N3PPdS: found C 51.36, H 3.49, N 6.29, S 4.84 %; 
calculated C 51.57, H 3.53, N 6.68, S 5.10 %. ESI-MS: m/z 630 ([M + Ht, 100%). 
5.3.4.2 Method B: Synthesis from Dimeric Complexes 
The dimeric complex (1 mol equiv.) was added to a stirred solution of 
triphenylphosphine (2 mol equiv.) in dry dichloromethane (5 cm3). The resulting 
orange reaction mixture was stirred at room temperature for 18 hours, at which time 
the reaction was a clear orange. Addition of hexane causes the product to precipitate 
and it is isolated by filtration and washed several times with boiling hexane. 
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5.3.4.2.1. [Pd(3,4-Dichloro-benzaldehyde thiosemicarbazone)(PPh3)CI] (32b) 
9 I 
""" N/NyNH, 
\ _5 
CI-P, 
PPh3 32b 
CI 
CI 
b 
The crude dimeric complex, [(3,4-dichloro-benzaldehyde thiosemicarbazone)PdCI]2 
(0.206 g, 0.317 mmol) was reacted with triphenylphosphine (0.169 g, 0.638 mmol) to 
give the product (32b) as a fluffy orange solid (0.101 g, 49 %). M.p.: 249-251 °C. 1H 
NMR (300.08 MHz, CDCI3): ~ (ppm) = 8.47 (m, 2H, Hb, He), 7.87 (d, J = 8.56 Hz, 1H, 
Hg), 7.70-7.80 (m, 6H, PPh3), 7.40-7.55 (m, 10H, PPh3, Ha), 4.93 (s, 2H, Hi). 13C 
NMR (75.46 MHz, CDCI3):. ~ (ppm) = 175.8 (Ch), 150.9 (Cg), 128.3-134.6 (Ca, Cb, Ce, 
Cd, Ce, Ct and PPh3). 31p NMR (121.47 MHz, CDCI3): ~ (ppm) = 27.10 (PPh3). IR 
(KBr, cm-1)u=3468 (m, N-H), 3365 (s, N-H), 1595 (s, C=N), 1581 (m, C=N), 1505 (s, 
C=C aromatics). Elemental Analysis for C27H23CbN3PPdS: found C 48.76, H 3.18, N 
5.67, S 4.65 %; calculated C 48.74, H 3.48, N 6.32, S 4.82 %. ESI-MS: m/z 615.95 
[M - Cit, 100 %. 
5.3.4.2.2. [Pd(3,5-Bis(trifluoromethy/)acetophenone thiosemicarbazone)(PPh3)CI] 
(33b) 
The crude dimeric complex, [(3,5-bis(trifluoromethyl)acetophenone 
thiosemicarbazone )PdCI]2 (0.204 g, 0.224 mmol), was reacted with 
triphenylphosphine (0.117g, 0.442 mmol) to give the product (33b) as a fluffy orange 
solid (0.060 g, 37 %). M.p.: 207-209°C. 1H NMR (300.08 MHz, CDCb): ~ (ppm) = 
8.19 (s, 2H, Ha, He), 7.93 (s, 1 H, He), 7.46-7.63 (m, 6H, PPh3), 7.36-7.45 (m, 9H, 
PPh3), 4.77 (s, 2H, HJ) 2.52 (s, 3H, Hh).13C NMR (100.58 MHz, CDCb): ~ (ppm) = 
172.1 (CI), 165.7 (Cg), 142.3 (Ct), 128.0-134.1 (Ca, Cb, Ce, Cd, Ce and PPh3), 123.1 
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(Ck, CI), 21.8 (Ch). 19F NMR (376.9 MHz, CDC's): ~ = -62.93 (C.E3). 31p NMR (161.90 
MHz, CDC's): ~ (ppm) = 29.22 (PPh3). IR (KBr, cm-1) u = 3446 (br s, N-H), 1624 (m, 
C=N), 1603 (m, C=N), 1513 (s, C=C aromatics). Elemental Analysis for 
C29H23CIF6N3PPdS: found C 47.86, H 3.28, N 5.37, 54.20 %; calculated C 47.56, H 
3.17, N 5.74, 5 4.38 %. ESI-MS: rn/z 695.98 [M - Cit, 100 %. 
5.3.4.3.3. [Pd(3,5-Bis(trifluoromethyl)benzaldehyde thiosemicarbazone)(PPh3)Clj 
(34b) 
34b 
The crude dimeric complex, [(3,5-bis(trifluoromethyl)benzaldehyde 
thiosemicarbazone)PdClb (0.201 g, 0.252 mmol), was reacted with 
triphenylphosphine (0.136 g, 0.519 mmol) to give the product (34b) as an orange 
solid (0.090 g, 46 %) . M.p.: 135-136 DC. 1H NMR (399.95 MHz, CDC's): ~ (ppm) = 
8.69 (s, 1H, Hg), 8.66 (s, 2H, Ha, He), 7.89 (s, 1H, He), 7.74-7.80 (m, 6H, PPh3), 7.45-
7.54 (m, 9H, PPh3), 5.01 (s, 2H, Hi). 13C NMR (100.58 MHz, CDC's): ~ (ppm) = 177.0 
(Ch), 149.6 (Cg), 128.4-134.6 (Ca, Cb, Ce, Cd, Ce, Ct and PPh3), 123.7 (Cj, Ck).19F 
NMR (376.9 MHz, CDCI3): ~(ppm) = -63.38 (C.E3). 31p NMR (161.90 MHz, CDCI3): ~ 
(ppm) = 27.74 (PPh3). IR (KBr, cm-1) u =3461 (s, N-H), 3341 (s, N-H), 1607 (s, C=N), 
1577 (w, C=N), 1491 (s, C=C aromatics). Elemental Analysis for C2sH21CIF6N3PPdS: 
found C 48.65, H 3.25, N 4.78, 53.83 %; calculated C 46.81, H 2.95, N 5.85, 54.46 
ESI-MS: rn/z 681.99 [M - Cit, 100 %. 
5.4. X-ray Crystallography 
X-ray single crystal intensity data were collected on a Nonius Kappa-CCD 
diffractometer using graphite monochromated MoKa radiation. Temperature was 
controlled by an Oxford Cryostream cooling system (Oxford Cryostat). The strategy 
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for the data collections was evaluated using the Bruker Nonius "Collect" program. 
Data were scaled and reduced using DENZO-SMN software.11 For complexes 30b 
and 32b, empirical absorption corrections using the program SADABS (Sheldrick, 
1996) were applied.12 
For all complexes, the structures were solved by direct methods and refined 
employing full-matrix least-squares with the program SHELXL-9713 refining on F2. 
Packing diagrams were produced using the program PovRay and graphic interface 
X-seed.14 and all non-H atoms were refined anisotropically. All hydrogen atoms, 
except the amino hydrogens H1A and H1B for complexes 26a, 27a and 28a and 
H1 Nand H2N for 30b, were included in idealised positions in a riding model with Uiso 
set at 1.2 or 1.S times those of the parent atoms. The amino hydrogens were located 
by difference Fourier methods and refined independently with simple bond length 
constraint. 
5.4. Biological Experiments 
5.4.1 Anticancer Experiments 
5.4. 1. 1 Cell lines 
The WHC01 cell line was derived from biopsies of primary oesophageal squamous 
cell carcinomas 15 and kindly provided by Professor Rob Veale (University of 
Witwatersrand, South Africa). KYSE - oesophageal squamous cell carcinoma cell 
lines previously established by Shimada and co-workers 16 were purchased from the 
German Resource Centre for Biological Material (http://www.dsmz.de). The cervical 
cancer cell lines HeLa and CaSki were obtained from the American Type Culture 
Collection (Rockville, MD, USA). All cultures were maintained in Dulbecco's Modified 
Eagle Medium containing 10% Foetal Calf Serum and 100U/ml streptomycin and 
100IJg/mi penicillin. Cells were maintained in a humidified 3rC, S% C02 incubator. 
5.4.1.2. IC50 Determination 
IC50 determinations were carried out using the MTT (3-(4,S-Dimethylthiazol-2-yl)-2,S-
diphenyltetrazolium bromide) assay. Briefly, 3000 cells were seeded per well in 96-
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well plates. Cells were incubated at 37°C and 5% C02 (24 h), after which aqueous 
DMSO solutions of each compound (1 OIJL, with a constant final concentration of 
DMSO = 0.2%) were plated at various concentrations. After 48 h incubation, 
observations were made, and MTT (10IJL) solution added to each well. After a 
further 4 h incubation, solubilization solution (100IJL) was added to each well, and 
plates were incubated overnight. Plates were read at 595nm on a BioTek microplate 
reader. WHC01 (oesophageal cancer cells of South African origin) cells were used. 
5.4.1.3. Western Blot Analysis 
Cells (0.5 x 106) were plated in 60mm dishes and incubated for 24 h, after which 
cells were exposed to concentrations of thiosemicarbazone 27 ranging from 0 to 
20IJM for 48 h. Cells were harvested in 601J1 of lysis buffer and following sonication, 
protein was quantitated using the Pierce BCA kit. Equal amounts of protein were 
loaded on a 10% polyacrylamide gel and subjected to electrophoresis at a constant 
current of 15 mAo After transfer at 100V for 1 h, membranes were blocked with 5% 
fat-free milk in tris-buffered saline with 0.1 % Tween 20 (TBSff) for 1 h at room 
temperature. After overnight incubation at 4°C with the primary antibody PARP 
(1:1000,5% milk) and ~-tubulin (1:1000, TBSffween) the membrane was incubated 
with horseradish peroxidase-conjugated antirabbit secondary antibody for 1 h at 
room temperature. Detection using Extended West Dura Super Signal (Pierce) was 
carried out and bands were visualized by autoradiography. 
5.4.2. Antimalarial Testing 
5.4.2.1. Chloroquine Sensitive (CQS) Strain of Plasmodium falciparum (D10) 
The test compounds were tested in triplicate on one occasion. Continuous in vitro 
cultures of asexual erythrocyte stages of P. falciparum were maintained using a 
modified method of Trager and Jensen.17 Quantitative assessment of anti plasmodial 
activity in vitro was determined via the parasite lactate dehydrogenase assay using a 
modified method described by Makler.18 The samples were prepared to a 2 mg/ml 
stock solution in 10% DMSO and sonicated to enhance solubility. Samples were 
tested as a suspension if not completely dissolved. Stock solutions were stored at -
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20°C. Further dilutions were prepared on the day of the experiment. Chloroquine 
(CQ) was used as the reference drug in all experiments. The percentage parasite 
survival was determined for all test samples at a single concentration (10 IJg/ml). 
Thereafter, a full dose-response was performed for all compounds showing a 
percentage survival less than 50 % to determine the concentration inhibiting 50% of 
parasite growth (ICsa-value). Test samples were tested at a starting concentration of 
100 IJg/ml, which was then serially diluted 2-fold in complete medium to give 10 
concentrations; with the lowest concentration being 0.2 IJg/ml. Complex 30b was 
tested at a starting concentration of 10 IJg/ml. The same dilution technique was used 
for all samples. CQ was tested at a starting concentration of 100 ng/ml. The highest 
concentration of solvent to which the parasites were exposed to had no measurable 
effect on the parasite viability (data not shown). The ICso-values were obtained using 
a non-linear dose-response curve fitting analysis via Graph Pad Prism v.4.19 
5.4.2.2. Chloroquine Resistant (CQR) Strain of Plasmodium falciparum (W2) 19 
Ring stage, W2-strain P. falciparum parasites (1% parasitaemia, 2% haematocrit) 
I were cultured in 0.5 mL of medium in 48-well culture dishes. Inhibitors from 10 mM 
stocks in DMSO were added to cultured parasites to give a final concentration of 20 
IJM. From 48-well plates, 125 IJM of culture was transferred to two 96 well plates 
(duplicates). Serial dilutions (1 :5) of inhibitors were made to final concentrations of 
10 IJM, 2 IJM, 0.4 IJM, 80 nM, 16 nM and 3.2 nM. Cultures were maintained at 37°C 
for 2 days after which the parasites were washed and fixed with 1 % formaldehyde in 
PBS. After two days, parasitaemia was measured by flow cytometry using the DNA 
stain YOYO-1 as a marker for cell survival. ICso-values for growth inhibition were 
determined with GraphPad Prism software from plots of percentage parasitemia of 
untreated control cultures against inhibitor concentration. 
5.5. General Procedure for Catalytic Experiments 
The aryl bromide (1 mmol), phenylboronic acid (1.5 mmol), sodium carbonate (2 
mmol) and water (1 ml) were added to 2ml of DMF in a round-bottomed flask fitted 
with a reflux condensor. A 1 mM stock solution of the palladium complex in DMF (1 
ml) was then added and the resulting reaction mixture was stirred at 100°C for 24 
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hours. Upon cooling to room temperature, distilled water was added and the 
products extracted with OeM. The organic phase was washed with brine and then 
dried over sodium sulphate, filtered and passed through celite. The volume of the 
organic phase was then concentrated to approximately 5 ml and the products 
analysed using gas chromatography. The conversions of the aryl bromide to product 
were calculated based on decane (0.1 ml) as internal standard. 
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